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1. Introduction 
 
Coronary artery disease (CAD) causes the death of hundreds of thousands of people all 
over the world every month. A crucial and common strategy for treatment involves vascular 
implants, which is not without its shortcomings in certain respects. This thesis therefore is 
concerned with a fundamental issue that governs the final outcome of this interventional 
therapy – the behavior of endothelial cells on the implant surface and how particular 
changes in the composition of that surface can potentially enhance implant performance. 
 
1.1. Anatomy of blood vessels 
Arteries, veins and capillaries form the most important transport system of the human body, 
providing continuous circulation of blood, nutrients, metabolites, respiratory gases, 
hormones, water and electrolytes. The significance of the circulatory system is illustrated by 
the fact that dysfunction results from just a few seconds of circulatory arrest, and 
irreparable brain damage ensues after 3-5 minutes [1]. 
The vessel wall itself is tripartite: the intima (tunica intima) contains endothelial cells only, 
the media (tunica media) is made up of smooth muscle cells and the underlying fibroblasts 
constitute the outer adventitia (tunica adventitia). The three layers of different cell types are 
separated by thin elastic laminae (figure 1.1). Different types of blood vessels are 
distinguished by morphological differences in the three layers. The wall thickness of veins is 
much smaller than that of arteries of comparable diameter. Thickness and cell density of 
the media differ in arteries such that they are categorized as arteries of the elastic type 
(thick intima with many elastic fibers, e.g. aorta) and arteries of the muscular type (higher 
density of smooth muscle cells in an overall thinner tunica intima). 
 
1.2. The endothelium 
1.2.1. General characteristics 
The endothelium is a monolayer of cells at the boundary of the bloodstream and the 
underlying tissue which makes it a crucial player in terms of nutrient supply as well as 
barrier function. Moreover, endothelial cells are instrumental in the formation and 
maintenance of blood vessels and the regulation of immune responses. They form the 
innermost layer of the wall of every blood vessel and thus fulfil the major task of keeping up 
the barrier between blood and vascularized tissue while regulating the molecular traffic 
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across that border. Other functions of the endothelium include the regulation of blood flow 
and vascular tone, contribution to vascular repair and homeostasis, modulation of 
haematopoietic cell proliferation, and the maintenance of an anti-coagulant surface [2]. An 
intact endothelium is inherently nonthrombogenic [3].  
 
1.2.2. Endothelial marker molecules 
On their surface, endothelial cells express a vast array of molecules that conduct 
interactions with other endothelial cells as well as with white blood cells. Adhesion 
molecules are paramount for the regulation of the barrier function of endothelial cells. Some 
of these lend themselves to closer scrutiny because they are very important in inflammatory 
settings such as after the implantation of a vascular graft or stent, and will therefore be 
briefly introduced here. 
PECAM-1 
Platelet endothelial cell adhesion molecule-1 (PECAM-1; CD31) is a cell surface 
glycoprotein concentrated in cell-cell junctions. In endothelial cells, it is important for 
mediating contact inhibition [4]. Modest levels of PECAM-1 expression are also found in 
platelets, neutrophils, monocytes and some T lymphocytes [5]. It has been shown that 
homophilic PECAM-1/PECAM-1 interactions are necessary for leukocyte transmigration [6]. 
Changes in shear stress, the force of friction on the vessel wall created by blood flow, lead 
to the abrupt dissociation of PECAM-1/endothelial nitric oxide synthase (eNOS) complexes, 
which makes PECAM-1 a chemical signal converter, a regulator of eNOS activation and a 
key molecule for detection of mechanoreception and –transduction [5]. Through alternative 
splicing, eight isoforms of PECAM-1 are generated [7], and gene polymorphisms have been 
linked to increased risk for severe coronary heart disease and myocardial infarction [5]. 
PECAM-1-/- double knockout mice have significantly reduced eNOS expression and nitric 
Figure 1.1. Schematic buildup 
of a blood vessel. Taken from 
lab.anbh.uwa.edu.au, Univer-
sity of Western Australia 
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oxide (NO) bioavailability (i.e. less intracellular NO) as well as impaired transendothelial 
leukocyte migration. At the same time they show reduced levels of endothelial cell 
apoptosis and of atherosclerotic lesions [5, 7]. Therefore PECAM-1 is regarded as a critical 
mediator of atherosclerosis [5] and as such has become a target in vascular 
immunotargeting with antibodies [8].  
ICAM-1 
Intercellular adhesion molecule-1 (ICAM-1) is constitutively expressed on the apical and 
basolateral surfaces of endothelial cells, and, albeit in orders of magnitude less, on 
leukocytes and fibroblasts [9]. It binds to the integrins LFA-1 and MAC-1 on the surface of 
leukocytes [10] and thus regulates their adhesion to endothelial cells. Through the 
transcription factor NF-B, ICAM-1 expression is upregulated by IL-1 and TNF- [11]. Along 
with VCAM-1 and E-selectin, it is therefore seen as a marker of an inflammatory phenotype 
of endothelial cells [12]. In PECAM-/- mice, ICAM-1 is downregulated [5]. Its participation in 
outside-in signal transduction impacts on inflammatory cell trafficking and leukocyte effector 
functions [9]. 
VCAM-1 
Vascular cell adhesion molecule-1 (VCAM-1) binds to the integrin VLA-4 on the surface of 
monocytes, basophils and eosinophils and thus facilitates their early attachment to 
endothelial cells [10, 11]. Together with ICAM-1, it is the most important adhesion molecule 
for the recruitment of white blood cells to sites of inflammation [9]. It is not constitutively 
expressed but induced by proinflammatory cytokines such as platelet-associated IL-1. In 
response to such a stimulus, the expression of VCAM-1 peaks earlier than that of ICAM-1 
[11]. 
 
1.2.3. Endothelial homeostasis  
The phenotype of endothelial cells depends on their location within the organism. Over 
twenty different kinds of endothelial cells have been morphologically characterized and are 
commercially available as primary cells. All of them grow as monolayers with a high density 
of adherens junctions and a more or less spindle-like cell shape.  
The interplay between endothelial cells, blood cells and smooth muscle cells is very 
intricate and requires an enormous degree of balancing and counterbalancing of the 
production and mediation of signaling molecules such as NO, cytokines, interleukins, 
interferons and colony stimulating factors [11]. For example, the endothelial barrier serves 
to shield the smooth muscle cells (SMCs) from circulating growth factors, while endothelial 
19 
 
cells also secret inhibitory factors, e.g. NO, against SMC proliferation [13]. Any 
dysregulation of that balance has the potential to shift the homeostatic situation towards a 
malicious path leading to vascular pathologies and on to cardiovascular disease. 
1.3. Clinical background 
1.3.1. Coronary artery disease 
Cardiovascular disease continues to claim the most lives in the industrialized world. Here 
the focus shall be put on CAD which affects tens of millions of people worldwide and is the 
most common cause of morbidity and mortality [14]. A very broad outline of disease 
progression could be sketched along the features of hypolipidemia, atherosclerosis and, as 
a consequence either of ischemia (localized lack of perfusion) or thrombosis (sudden 
obstruction of blood flow due to platelet aggregation), eventually acute myocardial infarction 
and heart failure. The latter is responsible for a third of all deaths [1]. Globally, 3.4 million 
women and 3.8 million men die of CAD every year [15]. Interventional procedures are 
usually required once the later stages of atherosclerosis have been identified and CAD is 
manifest. A key element for treatment is percutaneous transluminal coronary angioplasty 
(PTCA) which has become standard practice over the last two decades [14, 16].  
Even in early asymptomatic atherosclerosis, endothelial dysfunction is present and can be 
detected via assessment of the vasomotor regulatory function of the endothelium, e.g. by 
intravascular ultrasound or quantitative angiography upon infusion of acetylcholine or other 
vasoactive stimuli, or through peripheral arterial tonometry [2]. 
1.3.2. Atherosclerosis plaque 
1.3.2.1. Plaque formation 
Plaques are made of cholesterol, lipid and calcium and accumulate on the inside of blood 
vessels, and, once large enough, will restrict perfusion of the affected vessel (figure 1.2). 
As one of the first steps in atherosclerosis, monocytes adhere to endothelial cells. 
Following their transendothelial migration, they accumulate lipid deposits and transform into 
foam cells, secreting proinflammatory cytokines [17]. Plaque formation starts with 
intracellular accumulation of lipid in macrophages and smooth muscle cells of the intima 
[18]. Along with fibers from the extracellular matrix (ECM) and smooth muscle cells 
themselves, over time a so-called fatty streak is formed beneath the endothelium. These 
asymptomatic fatty streaks are frequently found even in young individuals [19]. But 
atherosclerosis is a slowly progressing disease with a long asymptomatic initial phase [2]. 
With time, fatty streaks may just disappear or, accumulating collagen and elastin as well as 
more lipid, turn into the subendothelial preatheroma, progressing to atheroma and 
fibroatheroma, with concurrent growth of the atherosclerotic lesion and disorganization of 
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the intima layer of the blood vessel (figure 1.2). In effect, atheromata (or ‘plaques’) 
represent asymmetric focal intimal thickenings [19]. The different stages of the disease can 
be diagnosed by clinical assessment of endothelial function, i.e. the response of affected 
vessels to endothelial dependent stimuli [2].  
The World Health Organization defines atherosclerosis as variable combination of changes 
in the intima of arteries, consisting of focal accumulations of lipids, complex carbohydrates, 
blood and blood components, connective tissue and calcium, associated with changes in 
the media [1]. The latter involve predominantly smooth muscle cell hyperplasia, 
characterized by migration of dedifferentiated and proliferating SMCs from the media to the 
intima, where they increasingly synthesize ECM.  
On the intracellular level, these cells generate much more protein by virtue of an enlarged 
rough endoplasmic reticulum and Golgi apparatus and increased number of ribosomes [18]. 
They are in the synthetic state, as opposed to the contractile, or quiescent state, where the 
contractile apparatus with its thick actin-myosin filaments fills 80-90% of the cytoplasm [18].  
On the molecular level, inhibitors of SMC growth (e.g. NO, heparin sulfate, transforming 
growth factor-β) regulate hyperplasia along with growth promoters (e.g. interleukin 1, 
platelet-derived growth factor, basic fibroblast growth factor).  
On the macroscopic level, lipid cores containing foam cells form between fibrous regions, 
obstructing the lumen of the vessel and leading to an outward ‘ulceration’ of the vascular 
wall in response to the narrowing [18]. This outward remodeling of the vessel wall can 
initially compensate for plaque growth [20] but is ultimately detrimental. As a result, arteries 
lose their elasticity and become increasingly rigid, or sclerotic, as calcification takes place. 
Muscular as well as elastic arteries are prone to atherosclerosis, especially in regions of 
curvature and bifurcation [21]. 
The most affected blood vessels in terms of plaque prevalence are: 1. abdominal aorta and 
iliac arteries, 2. coronary arteries, 3. thoracic aorta and femoral arteries, 4. aorta carotis 
interna, 5. brain stem arteries [1]. 
21 
 
 
1.3.2.2. Plaque activation and pathological features  
Extracellular matrix components, in particular collagen, and smooth muscle cells cap the 
intraluminal plaque. Infiltration of T cells, macrophages and mast cells ensues, and the 
production of inflammatory cytokines, matrix metalloproteinases (MMPs; they lyse matrix 
proteins and induce plaque rupture) and cysteine proteases leads to the activation of 
plaque and subsequent pathological events [19]. Atherosclerosis and CAD can be viewed 
as a state of unresolved inflammation [23]; neutrophils as ‘first responders’ of the innate 
immune system are responsible for the removal of cell debris, get directly in contact with 
plaque and thus promote its destabilization [24]. There is a direct correlation between this 
plaque destabilization, high amounts of MMP and a high neutrophil count [24]. The clinical 
symptoms of advanced atherosclerosis vary, as several mechanisms are at work: ischemia 
is caused by the slow narrowing of the vessel, hemorrhage into an atheroma or thrombosis 
is caused by the sudden occlusion of the blood vessel through a growing plaque, embolism 
may result from thrombosis, and the obstructed vessel may form aneurysms or even 
rupture because of its weakened wall [18]. A completely occluded coronary artery will 
cause a heart attack, i.e. acute ischemia of the surrounding cardiac tissue and death of the 
affected cardiomyocytes. In 60-70% of cases with coronary thrombosis, prothrombotic 
 
Figure 1.2. 
Pathogenesis and pro-
gression of atherosclerotic 
lesions (plaque). From 
Stary H et al. Circulation 
1995; 92:1355-1374 [22] 
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material is exposed to the blood as a consequence of plaque rupture [19]. Because of the 
life-threatening consequences, clinical intervention is very common. 
One important contributor to inflammation at the vessel wall is an imbalanced lipid 
metabolism. Excess low density lipoprotein (LDL) is retained in the intima and becomes 
modified by enzymes and oxidation [19]. Residing macrophages take up the resulting 
inflammatory lipids and turn into foam cells which are a major component of the plaque 
core. For this reason, hypercholesterolemia carries a high risk of atherosclerosis, which in 
turn is the direct cause of peripheral artery occlusive disease and CAD [19, 23].  
1.3.3. Treatment options 
Unless the arterial blockage is so severe that coronary artery bypass grafting (CABG) 
becomes necessary, the therapy of choice for obstructed blood vessels is their physical 
widening by means of balloon catheter and stent(s), i.e. coronary artery stenting (CAS). 
Mounted on a balloon catheter and aided by a guidewire and radiopaque dye, the stent is 
inserted into the obstructed segment and the balloon is inflated for 20 s to 3 min, 
embedding the stent in the arterial wall [15] and leaving behind a thin multilayered 
thrombus between the wall and the lumen. During stenting, the endothelial monolayer is 
inevitably compromised, as the vessel wall gets partially or completely denuded (figure 1.3). 
By means of scanning electron microscopy, it was demonstrated that the thrombus 
resolves around six to 12 weeks post-implantation, while the stented segment begins to be 
re-endothelialized [25]. Endothelial recovery, i.e. the formation of an intact lining of the 
blood vessel as well as of the inner surface of the stent, is crucial for the ultimate success 
of the implant. The advent of coronary stents has decreased the share of CABG to less 
than 20% of all coronary revascularization procedures performed [16]. However, a sizeable 
number of patients present with either re-stenosis or thrombosis after stenting, both of 
which are potentially life-threatening complications [26]. The main reason for these 
undesirable outcomes is a dysfunctional endothelium at the implant site. 
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1.3.3.1. Bare metal stents 
The first angioplasty was performed in 1964, the first balloon coronary angioplasty in 1977 
[28]. The first stents implanted into human patients were metal cylinders without any 
coating (bare metal stents, BMS). They have been in use since the mid-1980s. In the 
absence of complications, post-implantation vascular healing is linear [29] and re-
endothelialization is near complete by 3-4 months [30]. 
However, endothelial injury due to stenting (figure 1.3) can initiate a complex inflammatory 
cascade that may ultimately lead to thrombosis or in-stent restenosis [13, 31, 32] (figure 
1.4). The latter is the re-narrowing of the remodelled artery and is preceded by intimal 
hyperplasia, i.e. uncontrolled vascular smooth muscle cell proliferation and migration, as 
well as deposition of extracellular matrix and negative remodeling, eventually occluding the 
lumen of the stented vessel and requiring re-intervention in the form of so-called repeat 
revascularization procedures (also target lesion revascularization, TLR) [33]. In order to 
overcome widespread problems with a 30-40% TLR rate due to restenosis (from around 3 
months post-stenting) associated with the use of bare metal (or 1st generation) stents [34], 
drug-eluting (or 2nd generation) stents (DES) containing reservoirs of usually anti-
proliferative agents have been developed and found to reduce the restenosis rate sharply 
[35–37].  
Stent implantation is routinely accompanied by dual antiplatelet therapy with aspirin and 
thienopyridine for at least one month [38]. In the absence of these drugs, around 20% of 
emergency procedures following BMS implantation were due to stent thrombosis [30]. 
Nowadays, that incidence is down to 0.5-2% [30]. Depending on the time point after 
stenting, there is acute (<24 h), subacute (1 to 30 days), late (30 days and later), and very 
Figure 1.3.  
Mechanical trauma caused by 
stenting denudes the endothelium 
(green) locally and leads to multi-
layered thrombus formation. From 
Zimmer S and Nickenig G, Eur Heart 
J 2010; 31(21):2569-2571 [27] 
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late stent thrombosis (1 year and later) [39]. The majority of these thrombotic events occurs 
within the first six months of stenting [30]. 
 
 
 
 
1.3.3.2. Drug eluting stents 
Up to 40 per cent of the patients receiving first-generation BMS suffered from restenosis 
[34]. To reduce this rate of complications, coatings were developed to cover the metal struts 
of stents. In drug eluting stents (DES), the carrier polymer constitutes a reservoir for a drug 
that will be released either as the polymer degrades or through diffusion, and the kinetics of 
drug release can be tailored by polymer modification [15]. This modification can be 
achieved rather simplyby changing physical parameters such as surface area or coating 
thickness, or through complex chemical mechanisms generating covalent bonds between 
the drug and the polymer [37]. The number of cases where repeat revascularization was 
needed indeed dropped by 70% [33]. Depending on age and general health of the patients, 
the incidence of restenosis after DES implantation can drop as low as 3% [41]. So even 
though the first DES was approved in 2003, by 2006 DES had around 80% market share in 
the U.S. [30]. A detrimental side effect of DES is delayed endothelial healing coupled with 
an increased risk of in-stent thrombosis [31, 37] (figure 1.4). This is in part due to thicker 
struts necessary to make up for reduced radial strength [26]. The long-term efficacy of DES 
was callled into question when it became apparent that the rates of late and very late stent 
thrombosis (ST) were problematic. Dual antiplatelet therapy is consequently prolonged to at 
least 12 months after DES implantation [38]. A meta-analysis found the incidence of early 
and late ST not to be statistically different between patients treated with BMS or DES, but 
most cases of very late ST were associated with DES [30]. This has been attributed to a 
host reaction in the vessel wall to durable polymers [32], which in general incite greater 
inflammation than the bare metal alternative [30]. Other causes of late-stage ST include 
Figure 1.4. Post-operative complications commonly associated with DES and BMS. Modified 
from Curfman GD et al.: N Engl J Med 2007; 356:1059-1060 [40] 
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increased platelet aggregation or inflammation due to exposed stent struts [42]. Although 
these complications are still very rare (the annual incidence of very late ST is only 0.2-
0.6%), their severity (with a 50% incidence of myocardial infarction and a 20% mortality rate 
as a consequence of ST) makes further improvements mandatory [31]. Thus, in order to 
enhance DES safety and long-term efficacy, various approaches aim at simultaneous 
promotion of endothelial proliferation and inhibition of neointimal proliferation [37]. The most 
recent generation of bioabsorbable stents is targeted especially towards younger patients, 
who are less likely to require procedural reintervention and thus will benefit most from such 
transient implants. A clinicial trial with the AMS (absorbable magnesium stent) platform has 
found that the stent was fully adsorbed after 4 months. This period might even be shortened 
in favor of restoration of vasomotor function, but the time over which stented arterial 
segments really need mechanical scaffolding has not yet been conclusively determined 
[37]. 
Despite the multitude of manufacturers and stent platforms on the market today, the drugs 
commonly used in DES all derive from two conventional anti-restenosis agents. The first is 
the immunosuppressive agent sirolimus, also known as rapamycin, which was discovered 
in Streptomyces hygroscopicus on the Pacific island Rapa Nui in 1964 [33] and originally 
developed as antifungal compound [16]. It prevents cell cycle transition from late G1 into S 
phase by binding to the intracellular receptor Fk506-binding protein 12 (FKBP12) and 
inhibiting the kinase mammalian target of rapamycin (mTOR), in turn preventing 
degradation of the cyclin-dependent kinase inhibitor p27kip1. Therefore it acts as an 
unspecific inhibitor of mammalian cell proliferation, i.e. including all cells involved in 
vascular healing following stent implantation [29]. Consequently, the reendothelialization 
process of DES surfaces is delayed compared to BMS, where it is nearly complete about 3-
4 months following implantation (figure 1.5). In contrast, a histological study found 
approximately 80% endothelialization of the sirolimus eluting Cypher stent 16 months after 
stenting [30]. Since 2003, sirolimus has been used in commercial DES and a number of 
sirolimus analogs have been developed to improve on safety and efficacy. For example, 
everolimus contains a side chain alkylated with a 2-hydroxyethy group, leading to 3-fold 
affinity to FKBP12 and 2- to 5-fold lower immunosuppressive activity than sirolimus [33]. 
Zotarolimus contains a tetrazole ring in the C40 position, giving it 3- to 4-fold lower 
immunosuppressive activity than sirolimus, with unchanged FKBP12 affinity and 
antiproliferative activity [33]. The semisynthetic sirolimus analog biolimus-A9 contains an 
extra alkoxy-alkyl group, making it highly lipophilic while maintaining the antiproliferative 
potency [33]. Other Limus derivatives are myolimus, pimecrolimus and tacrolimus, with the 
latter exerting its antiproliferative effects somewhat differentially on human vascular SMCs 
and endothelial cells [37]. 
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The other drug commonly used in DES is the cytostatic agent paclitaxel, first isolated from 
the bark of Taxus brevifolia in 1971. Unlike sirolimus, it arrests the cell cycle irreversibly in 
G2/M phase, by binding to the β-subunit of tubulin heterodimers and thus interfering with 
mitotic spindle formation [33] and blocking cell proliferation. Sustained release of paclitaxel 
has been used in commercial DES since 2004 and has been shown to reduce neointima 
formation by about 50%, compared to paclitaxel-free stents [30]. At present, paclitaxel is 
also the only cytostatic drug used in drug eluting balloons (DEB), devices used on patients 
unable to be stented. The clinical success rate of DEB has been found to lie between that 
of BMS and DES [38]. 
Table 1.1 gives an overview of commercially available drug eluting stents and the particular 
drugs incorporated into them. 
Drug Drug eluting stents (manufacturer) 
Sirolimus AMS 4.0 (Biotronik), Cypher, Cypher Select (Cordis),  
Excel (JW Medical Systems), Nevo (Johnson & Johnson), 
Ideal Biostent (Xenogenics) 
Biolimus-A9 Axxess Plus (Devax), Biofreedom (Biosensors),  
Biomatrix (Biosensors), Nobori (Terumo) 
Everolimus BVS (Abbott), Promus Element (Boston Scientific), 
Xience-V (Abbott) 
Zotarolimus Endeavor, Endeavor Resolute (Medtronic) 
Paclitaxel AMS 3.0 (Biotronik), Conor (Conor Medsystems),  
Taxus, Taxus Express, Taxus Liberté (Boston Scientific) 
Table 1.1. Antiproliferative drugs and corresponding DES commonly used in current clinical practice. 
Figure 1.5.  
Stent endothelialization by 
comparison. Representative SEM 
micrographs of 4 DES (eluting 
sirolimus (SES), paclitaxel (PES), 
zotarolimus (ZES) and everolimus 
(EES), respectively) and a BMS 
harvested from rabbit iliac arteries 
14 days post stenting. Insets are 
200× magnified. Modified from 
Joner et al. J Am Coll Cardiol 
2008; 52(5):333-342 [43] 
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Unfortunately, while the immunosuppressive activity, especially on T cells, has been 
successfully reduced with some sirolimus analogs, they still exert their antiproliferative 
effect on endothelial cells, too. The same is true for paclitaxel (PES in figure 1.5). Because 
of their detrimental side effect on endothelial function, antiproliferative drugs as well as 
permanent polymers are likely causes of late ST and adverse cardiac events [30, 37]. 
Ongoing efforts to improve DES performance include the development of new polymers 
and polymer blends, optimization of drug release through coating architecture (intra-strut 
wells) and combination of antiproliferative agents with other drugs, for example sirolimus 
and triflusal (inhibitor of platelet cyclooxigenase, i.e. antithrombotic) or zotarolimus and 
dexamethasone. 
While no selective inhibitor of SMC proliferation has been found yet, novel drugs are under 
investigation that efficiently inhibit these cells without compromising endothelial cell 
function. 
1.3.3.3. Vascular grafts 
In aortic and iliac surgery, where segments of relatively wide (diameter > 7 mm) blood 
vessels are replaced, synthetic vascular grafts rather than stents are widely used. Smaller 
diameter grafts are also available but their use is limited because of problems with intimal 
hyperplasia and surface thrombogenicity, resulting in comparatively poor long-term 
performance [44]. In the short term, there is practically no spontaneous endothelialization of 
small diameter synthetic grafts [45]. That is why autologous vein grafts are currently the 
best treatment option for small diameter applications [46].  
Artifical blood vessels for tissue engineering are mostly made up of expanded 
polytetrafluoroethylene (ePTFE, teflon), polyethylene terephthalate (PET, Dacron) or 
polyurethane, i.e. polymers that are well suited mechanically to withstand shear stress and 
blood pressure, but that are also characterized by their tendency to act prothrombogenic 
[47]. Especially for the larger diameters, an attempt to overcome such complications was 
made with the introduction of fully bioresorbably scaffolds [32]. They safeguard the 
mechanical compliance of the affected vessel by initially providing scaffolding and then 
restoring physiologic function by disappearing altogether. Properties of existing synthetic 
materials that are detrimental to cell adhesion can also be overcome by coatings with ECM 
proteins or peptides derived from them [48, 49]. For example, the cysteine-alanine-glycine 
(CAG) trimer found in collagen type IV, mixed in with PCL, provides small-caliber grafts with 
patency for over 2 years in vivo [50]. 
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1.4. Polymers as biomaterials 
1.4.1. General characteristics 
Polymers are made up of repetitive monomers. The monomers form chains that can be 
either crosslinked, branched, star-shaped or linear [51]. Depending on the arrangement of 
the monomers, the polymer as a whole is either amorphous or crystal-like. Chemical 
properties are also decisive in determining whether a polymer is biostable or 
biodegradable. Chemical bonds in biodegradable polymers can be cleaved under in vivo 
conditions, often enzymatically or by hydrolysis [52]. For physiological elimination of the 
degradation products, an important consideration in polymer selection is that the 
breakdown process sets in once those products have been reduced to a molecular weight 
of less than 50,000 g/mol [51]. 
The use of biomaterials for clinical applications is very widespread, as they are part of 
wound covers, dental and bone implants, cardiovascular stents and artificial organs. 
Biopolymers are derived from natural sources (e.g. collagen, chitosan, hyaluronic acid) as 
opposed to synthetically produced polymers. 
Biostable polymers will not be degraded under physiological conditions and are therefore 
regarded as inert. There are, however, problems with temperature dependent deformation 
and long-term hydrolysis and oxidative degeneration of these polymers. Examples include 
polymethyl methacrylate (PMMA) used in dental fillings, artificial teeth or as bone cement, 
polyetheretherketone (PEEK) used in spinal devices, hip prostheses, heart valves and 
stents, polysiloxane used in breast implants, artificial tendons and joints and PTFE used in 
artificial blood vessels [53]. 
Biodegradable polymers are commonly employed in suture material, tissue engineering 
scaffolds and as carriers in drug delivery systems. Conceptually, their use avoids the 
problem of long-term inflammation, as they become gradually replaced by host tissue. This 
also enables their use in children without compromising growth processes [51]. 
1.4.2. Foreign body reaction to biomaterials  
In general, the insertion of implants or implant-related material into a living organism is 
associated with an immune response to that foreign body. This foreign body reaction (FBR) 
is sometimes described as encompassing the whole series of host reactions initiated by the 
implantation process [54], and sometimes referred to only as the end stage of those 
responses [55]. In any event, before host cells interact with an implanted device, the latter 
initially acquires a layer of host proteins. Local injury and contact with blood lead to 
unspecific adsorption of proteins such as fibrinogen on the implant surface [52, 55]. This 
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deposition of plasma protein equals the formation of a blood based provisional matrix, from 
which bioactive agents such as cytokines and other soluble mediators are released to 
modulate the subsequent wound healing response [55]. The provisional matrix at the 
tissue/material interface is the initial thrombus to which monocytes will trigger an acute 
inflammatory response: mediated by mast cells secreting IL-4 and IL-13, neutrophils are 
attracted to the implant site and monocytes will adhere [55, 56]. Depending on the extent of 
implantation-induced injury and the tissue involved, acute inflammation resolves within 
minutes to days [54, 55]. 
The early stage of FBR is followed by a chronic inflammatory stage, during which 
lymphocytes and plasma cells are transiently present [55, 56]. Under the influence of IL-4 
and IL-13 derived from mast cells and T lymphocytes, the adherent monocytes differentiate 
to macrophages [55–57]. Maximum infiltration with macrophages, the principle cellular 
player in FBR, occurs within three days [54]. The cytokine stimulus activates them such that 
the mannose receptor, important for mediating phagocytosis and endocytosis, becomes 
upregulated and the monocyte-derived macrophages fuse to form multinucleated foreign 
body giant cells (FBGCs) [55–57]. This process occurs from seven to 14 days following 
implantation [55]. Regardless of implant durability, the first two to four weeks of its presence 
are the period in which the FBR is influenced by material properties [55]. Once 
inflammation is resolved, the wound healing response progresses with infiltration of 
fibroblasts and the separation of a one- to two-cell layer of macrophages and FBGCs from 
the implant: granulation tissue develops [55]. This is the precursor to fibrotic encapsulation 
of the implant [55, 57]. Fibrous capsule formation can seriously compromise implant 
function. The other major FBR-associated deleterious effect is biomaterial degradation 
through release of esterases, lipases, oxidants and other bioreactive intermediates by 
macrophages and FBGCs [55, 57]. Depending on the implant material, this degradation can 
impair function or result in device failure [55, 57]. 
Depending on the severity of the foreign body reaction, the following categorization of 
biomaterials has been established: 1. toxic materials, which promote cell death in the 
surrounding tissue, 2. inert materials, which become encapsulated by a fibrotic reaction, 3. 
bioactive materials, which allow for extensive interaction with and integration into the 
surrounding tissue and 4. biodegradable materials, which become replaced by autologous 
tissue and allow complete tissue regeneration [58]. 
1.4.3. Surface modification of polymers 
In order to reduce inflammatory reactions to biomaterials and improve their interaction with 
the surrounding tissue, the surface is commonly altered, leaving the bulk characteristics of 
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the material mostly unchanged. Chemical activation of the polymer surface involves the 
generation of functional groups. These can interact with chemical motifs present on the cell 
surface much more readily than the otherwise inert polymer itself [59]. Depending on the 
type of the functional group, different bonds with extracellular molecules can be formed. 
Ester bonds that are formed upon the previous generation of hydroxyl groups, for example, 
are easily cleaved, whereas generation of amino groups allows the formation of 
physiologically more stable amid bonds [51]. Functional groups are also necessary to 
couple biomolecules (e.g. amino acids, polysaccharids, enzymes) to the polymer, and they 
can be generated by plasma chemical, wet chemical or photochemical modification. 
Plasma activation means modification with ionized gas. Practically all polymers can be 
modified this way, and the kind of modification can be controlled by the gas employed. For 
example, oxygen plasma will generate hydroxyl groups, while nitrogen plasma will generate 
amino groups on the polymer surface. The depth of plasma activation is limited to about 5 
nm [60]. 
Wet chemical modification potentially reaches further down into the polymer bulk, 
depending on reaction conditions, e.g. solvents used in the process. For example, sodium 
hydroxide can be used to break ester bonds and increase the number of functional groups 
on the polymer surface. 
Targeted local modification is possible through photochemical modification, where the 
polymer is subjected to high-energy ultraviolet radiation. This breaks chemical bonds and 
releases free radicals which in turn leads to crosslinking or generation of functional groups 
[61]. 
Another form of surface functionalization is the concept of biomimetic coatings. Here 
adverse host responses are avoided by the generation of 3D scaffolds supporting cell 
adhesion, growth and differentiation [62]. Whereas biomimetic materials can be made up 
entirely of ceramics, metal or synthetic polymers, biomimetic coatings utilize biological 
substances such as fibronectin, collagen, vitronectin or other macromolecules from the 
extracellular matrix to cover non-biological materials [62]. They are applied in vascular 
stents, tooth or bone implants. 
 
1.5. Concept of biocompatibility 
Biocompatibility is the ability of a material to perform with an appropriate host response in a 
specific application, marked by the absence of adverse effects [63]. More precisely, it is the 
sum of all material characteristics that relate to tissue integration and direct interaction with 
cells and their adhesion, growth, and differentiation [62]. 
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For any implant material, it is essential that it is well tolerated by the receiving organism. 
Material-induced complications such as inflammation need to be minimized as much as 
possible. This can be achieved through a multitude of manipulations of the material in 
question, such as coating with ECM proteins or surface roughening by mechanical or 
chemical methods [62]. Therefore a multi-stage testing process must be undergone by new 
materials in which in vitro testing precedes animal and clinical testing. In cell culture 
experiments, viability and proliferation tests are proven methods to assess cytotoxicity and 
biocompatibility of new materials. For cell viability, several assays are available in which 
enzymatic activity can be assessed by comparison to appropriate controls. Often aided by 
changes in fluorescence patterns, the reaction of enzyme and substrate can be reliably 
measured on the premise that the more viable the cells are, the more metabolic activity 
there will be to detect. 
 
1.6. VEGF and angiogenesis 
1.6.1. Molecular variety of the VEGF family 
Vascular endothelial growth factor (VEGF) is specific for endothelial cells. Its two major 
biological effects are the control of vascular development during embryogenesis and the 
control of blood and lymph vessel function in the adult [64]. The family of five mammalian 
VEGFs (types A, B, C, D and placental growth factor, PlGF) is multiplied further by 
alternative splicing and processing [65]. As a result of 14 alternative splicing events, 
combined with two polyadenylation signals, two promoters and eight exons, the human 
VEGF-A gene can give rise to 56 potential mRNAs [66]. Because it contains the largest 
variety of regulatory elements, VEGF-A mRNA has been coined a paradigm for complex 
regulation of gene expression at the post-transcriptional level [66]. The various mRNAs are 
translated into either free soluble proteins that primarily act as endothelial mitogens, or 
heparin-binding surface proteins that control vascular permeability [67]. VEGF family 
members regulate all types of vascular growth, i.e. sprouting of capillaries from pre-existing 
capillaries (angiogenesis), generation of muscular collateral vessels form arteriolar 
anastomoses (aretiogenesis) and lymph vessel growth from pre-existing lymphatic vessels 
(lymphangiogenesis) [68]. During embryonic development of the vasculature, VEGF-B, 
VEGF-D and PlGF seem to not be required, whereas VEGF-A and VEGF-C are essential 
[68]. How critical a factor in vascular development VEGF really is is illustrated by the fact 
that targeted inactivation of a single murine VEGF allele results in early embryonic lethality 
[69]. Apart from being essential and rate-limiting in physiological angiogenesis [70], VEGF 
also facilitates re-endothelialization of the lining of vessels that get inevitably damaged 
during stent implantation [71]. VEGF-A expression becomes progressively increased in 
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atherosclerosis and in-stent restenosis, which is thought to be a secondary effect of local 
hypoxia and inflammation [68]. Upregulation of VEGF-A is also important for tissue repair 
and for angiogenesis in skeletal muscle induced by physical exercise [68]. The angiogenic 
effect of VEGF is mediated first and foremost by the production of nitric oxide [7]. 
1.6.2. VEGF receptors 
The various isoforms of VEGF exert their effects through three structurally related receptor 
tyrosine kinases and affinity-increasing coreceptors (such as neuropilins 1 and 2 and 
integrins). VEGF receptor-1 (VEGFR-1, also called Flt-1) as a receptor for PlGF and VEGF-
B is important for recruitment of myelomonocytic cells in inflammatory responses [64]. 
VEGFR-2, also called Flk-1 or kinase-insert domain-containing receptor (KDR), mediates 
the mitogenic function of VEGF-A, as well as its effects on endothelial cell migration, 
invasion and microvascular permeability [72]. VEGFR-3 only binds the large precursors and 
proteolytically cleaved forms of VEGF-C and –D, with the processed forms having increased 
receptor affinity and more angiogenic potential, while the unprocessed precursors mainly 
promote lymphangiogenesis [68, 72]. Differential ECM-binding properties and proteolytic 
processing of its multiple isoforms drive an interplay between diffusible and ECM-bound 
VEGF that is the basis for angiogenic gradients shaping the vascular system [65]. The 
chemotactic effect of VEGF on endothelial cell migration is mediated through VEGFR-2 and 
phosphorylation of eNOS by the protein kinase Akt [73]. Other molecules required for 
VEGF signal transmission include VE-cadherin, β-catenin, PI3 kinase and Bcl-2 [69]. This 
signalling pathway induces lamellipodia formation in endothelial cells [74].  
1.6.3. Animal models 
In animal models, VEGF has been reported to reduce neointimal area [75]. Suppression of 
SMC proliferation, as well as antithrombotic and vasodilative effects appear to be mediated 
through low local concentrations of VEGF-A [68]. However, intimal hyperplasia can also be 
induced by VEGF when released from ePTFE grafts [76]. Medium concentrations (150 
ng/d) of VEGF induce a constant increase in vascularisation even after VEGF supply 
ceases, as opposed to transient (if higher) vessel growth into porous scaffolds with high 
concentrations (1.5 µg/d) of VEGF [70]. 
Among the widespread effects of VEGF is the upregulation of endothelial NO synthase 
(eNOS) [70] as well as inhibition of platelet and leukocyte activation and of smooth muscle 
cell proliferation [28]. All of these are desirable outcomes in the context of vascular stent 
implantation, which served as motivation here to test the effects of VEGF stimulation on 
human umbilical vein endothelial cells (HUVECs) growing on a functionalized biopolymer. 
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1.7. The extracellular matrix 
1.7.1. Molecular composition 
The extracellular matrix (ECM) is a highly complex mesh made up of fibrous proteins, 
proteoglycans, hyaluronic acid and other glycosaminoglycans. The proteoglycans, 
consisting of a protein at the core and up to 95% carbohydrate, form a hydrogel in which 
fibrous proteins are embedded [77]. Proteoglycans also act as growth factor carriers and 
regulators of matrix assembly [62] and, by virtue of their highly sulfated, negatively charged 
glycosaminoglycan side chains, are responsible for turgor, elasticity and biomechanical 
pressure resistance of many tissues [62]. Abundant proteins of the ECM include elastin, 
collagen, fibrillin, vitronectin, laminin and fibronectin. These are mostly glycoproteins in 
which the carbohydrate content is less than 60% [77]. Abundant proteoglycans are versican 
in the skin and aggrecan in cartilage, present mostly in large complexes with hyaluronic 
acid. The exact biochemical composition, geometry and density of the ECM varies greatly 
from tissue to tissue, but in every instance provides a reservoir of signaling molecules and 
structural support that determine the anchorage and behavior of cells [76]. Moreover, the 
ECM has an impact on the metabolism of cells, their shape, development, migration, and 
proliferation [77]. Integrins on the cell surface and peptide epitopes contained in ECM 
molecules are crucial in mediating signals between cells and the ECM. 
Most of the ECM proteins can be crosslinked through adapter molecules such as heparin 
sulphate, or can form complex heterodimers and heterotrimers [78]. For example, the 
laminin family consists of about 20 different heterotrimeric glycoproteins [62]. Fibronectin 
consists of two very large subunits (each almost 2,500 amino acids long) that each contain 
domains for binding heparin, integrin and collagen [77]. The three-dimensional makeup of 
the ECM molecules, its density, stiffness and other physical properties are more indirect 
cues for cell growth, differentiation and migration [62]. 
The synthesis of ECM components is also a hallmark of tissue inflammation. In the context 
of atherosclerosis, the arterial wall produces fibrils and fibers that entrap lipoproteins which 
can then associate with matrix components – the beginning of plaque formation. Further 
growth of the plaque involves an enormous upregulation of collagen production, up to a 
point where it constitutes 60% of the plaque itself [24].  
1.7.2. The role of the ECM in implant biology 
Molecules from the ECM or cell adhesive peptides derived from such molecules are widely 
used in implants and tissue engineering to functionalize synthetic surfaces, as they promote 
adhesion and proliferation of endothelial cells [48, 76]. The ECM itself has become a 
therapeutic target for inflammatory diseases in general: so-called protective ECM mimetics 
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are under development as therapeutic devices [24]. Coating with adhesive molecules from 
the extracellular matrix is one of three basic strategies to design biomimetic materials [62]. 
Because of the reported pro-endothelialization effects, this study includes the coating of a 
polymer with three different matrix proteins. 
 
1.8. PCL as biomaterial 
In the context of tissue engineering and artificial heart valves, polycaprolactone (PCL) is 
well investigated and distinguished by its biodegradability [79] and comparatively fast 
endothelialization [19], along with a lack of toxicity [46]. Degradation of this biodegradable 
aliphatic polyester happens predominantly through nonenzymatic hydrolytic cleavage [80]. 
In vivo, this leads to a breakdown of the PCL chain structure (figure 1.6) into low molecular 
weight fragments, which eventually can be phagocytosed. In rats, degradation studies of 
implanted PCL have found the molecular weight of the polymer reduced by 20-30% over 
three to six months, depending on arterial pressure and blood flow (reviewed in [81]). 
 
Figure 1.6. Chemical structure of poly(є-caprolactone) 
PCL was initially developed to be used in bioabsorbable surgical threads for bone sutures 
[62], but, interestingly, has also been used as a long-term contraceptive device [19]. In the 
cardiovascular setting, PCL is currently under investigation as scaffold material for small 
diameter vascular grafts in the treatment of CAD. Compared to the standard ePTFE used in 
large diameter grafts, it has been found to allow faster ECM formation and 
endothelialization and to facilitate the vascular healing process better: in a study where 
electrospun PCL nanofiber grafts (inner diameter 2 mm) were implanted into rat infrarenal 
abdominal aorta, the luminal surface of the prostheses showed 97% endothelial coverage 6 
weeks later, and 100% at 12 weeks after implantation [81]. Concurrently, only a thin layer of 
neointima formed that stopped growing around 18 weeks after implantation. Another 
favorable PCL graft healing characteristic demonstrated in that study was low level chronic 
foreign body reaction, as evidenced by 50-60% transmural cellular infiltration of the graft 
body by macrophages and fibroblasts after 12 weeks, without any signs of chronic 
inflammation [81].  
Another example for the biomedical use of PCL is the sirolimus loaded Xinsorb 
bioresorbable scaffold, where PCL is part of the polymer blend and which in an 
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experimental in vivo study in the porcine coronary artery model was shown to cause less 
restenosis (in terms of percentage of the implanted segment’s diameter) than the sirolimus 
eluting Excel stent (reviewed in [32], see table 1). Moreover, electrospinning as the means 
of PCL scaffold production was reported to convey additional benefits for directional 
mechanical properties through engineered complex nanofiber orientation architecture with 
ECM-mimicking structures [46].  
Here different morphologies and differently activated surfaces of PCL are systemically 
examined, as well as the impact of a growth factor stimulus, with respect to its potential as 
implant material with optimized properties for endothelialization. 
 
1.9. Research aims and motivation 
Taking the clinical experience with currently used cardiovascular stents and grafts into 
account, enhancing the stent surface for colonization with endothelial cells is a prerequisite 
for the accelerated formation of an intact endothelium at the implant site. Although 
numerous approaches in that regard have been made and in part even been transferred to 
the clinical practice, no solution has yet been found that yields smooth and quick 
endothelialization of the implant. Creating a truly endothelial-friendly implant surface is one 
of the biggest challenges in designing new vascular devices. Once the effect of a certain 
stimulus is established, the question arises how to best incorporate the molecule of interest 
into a biomaterial. The luminal surface is where the interaction with the patient’s blood and 
immune system occurs, making it the target point for biomaterial designers to exert the bulk 
of mechanical and chemical engineering. Singling out PCL as a model polymer, this thesis 
is therefore concerned with a systematic study of the effect of a multitude of polymer 
surface modifications on the behavior of endothelial cells in vitro. 
In addition, surface coating of the modified polymer with ECM proteins and cell stimulation 
with a specific growth factor are applied in an attempt to make use of biomolecules to 
facilitate the growth of endothelial cells on the biomaterials under investigation. It is clear 
that the in vitro examination of molecules responsible for interendothelial contact (and 
hence for barrier function) is useful for determining a biomaterial’s endothelial cell 
compatibility [82]. Yet there are comparatively few studies looking at the molecular 
crossroads of signal transduction that becomes modulated by modification of the surface 
the signaling cells adhere to. Therefore important marker molecules for endothelial function 
have been selected here for quantitative gene expression analysis, to gain insight into what 
mechanisms on the molecular level might be at the root of differential cell behavior. 
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After establishing a suitable in vitro model for the evaluation of specific surface 
modifications of a model polymer and their effects on polymer endothelialization, the work 
undertaken during the course of this thesis is to provide answers to the following questions: 
1. Which PCL modification increases endothelial cell adhesion the most? 
2. Are there additional benefits to be had by endothelial cell stimulation with VEGF? 
3. Can cumulative pro-endothelialization effects be achieved by PCL coating with ECM 
proteins? 
4. In what way will the different polymer modifications alter mRNA expression of 
selected endothelial cell marker molecules? 
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2. Materials and Methods 
 
2.1. Reagents and materials 
2.1.1. Chemicals 
All chemicals were of p. a. quality or higher and ordered from one of the following suppliers: 
Boehringer Ingelheim (Ingelheim), GibcoBRL (Life Technologies, Carlsbad, U.S.), 
Invitrogen (Life Technologies, Carlsbad, U.S.), Roche Molecular Biochemicals (Grenzach-
Wyhlen), Sigma-Aldrich (Seelze), Mallinckrodt Baker (Griesheim), Serva Feinbiochemica 
(Heidelberg), Thermo Fisher Scientific (Karlsruhe) or Merck (Darmstadt). Industrial grade 
poly(є-caprolactone) (PCL, CAPA 6800, M = 80,000 g/mol) was from Perstorp Holding AB 
(Warrington, U. K.). 
2.1.2. Culture media and solutions 
The following were prepared from commercially available ingredients: 
Name Ingredients  
 
human umbilical 
vein endothelial 
cell (HUVEC) 
growth medium 
 
10% (v/v) fetal calf serum (FCS; GibcoBRL), 0.1 ng/ml 
epidermal growth factor (EGF; Biomol, Hamburg), 1 ng/ml 
basic fibroblast growth factor (bFGF; Biomol, Hamburg), 5 U/ml 
heparin (Biochrom/Merck Millipore, Berlin), 1 µg/ml 
hydrocortisone (Sigma-Aldrich), 0.4% (v/v) endothelial cell 
growth supplement (ECGS; PromoCell, Heidelberg), 100 µg/ml 
penicillin (GibcoBRL), 100 µg/ml streptomycin (GibcoBRL), 2 
mM L-glutamine (GibcoBRL) in MCDB131 reduced serum 
supplemented medium (PAN Biotech, Aidenbach) 
HUVEC arrest 
medium 
0.5% (v/v) FCS, 0.1 ng/ml EGF, 1 ng/ml bFGF, 5 U/ml heparin, 
1 µg/ml hydrocortisone, 0.4% (v/v) ECGS, 100 µg/ml penicillin, 
100 µg/ml streptomycin, 2 mM L-glutamine in MCDB131 
reduced serum supplemented medium 
EC basal 
medium 
2.5% (v/v) FCS, 100 µg/ml penicillin, 100 µg/ml streptomycin, 2 
mM L-glutamine in MCDB131 reduced serum supplemented 
medium 
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Name Ingredients  
human coronary 
artery endothelial 
cell (HCAEC) 
growth medium 
5% (v/v) FCS, 0.4% (v/v) ECGS, 10 ng/ml recombinant human 
EGF, 1 µg/ml hydrocortisone, 22.5 µg/ml heparin in endothelial 
cell growth medium (PromoCell, Heidelberg) 
 
10 phosphate 
buffered saline 
(PBS)  
1.5 M sodium chloride, 100 mM sodium 
hydrogenorthophosphate, 40 mM potassium dihydrogen 
orthophosphate, adjusted to pH 7.4 
Live/dead stain 
solution 
0.00125% (v/v) calcein AM (Invitrogen), 0.0025% (v/v) ethidium 
homodimer (Invitrogen) in PBS (pH 7.4) 
Phalloidin stain 
solution 
Phalloidin-FITC (1 µg/ml; Sigma-Aldrich), 0.0025% (v/v) 
ethidium homodimer (Invitrogen) 
Table 2.1. Culture media and solutions. 
 
2.1.3. Primers for quantitative real-time PCR 
primer 
name 
gene name primer sequence PCR 
product 
size 
NCBI 
reference 
sequence 
 
eNOS 
qFwd 
 
nitric oxide synthase 3 
(endothelial cell) 
(NOS3) 
 
GAG ACT TCC GAA 
TCT GGA ACAG 
 
102 bp 
 
NM_000603.4 
eNOS 
qRev 
nitric oxide synthase 3 
(endothelial cell) 
(NOS3) 
GCT CGG TGA TCT 
CCA CGTT 
102 bp NM_000603.4 
ICAM-1 
qFwd 
intercellular adhesion 
molecule 1 
TTG AAC CCC ACA 
GTC ACC TAT 
190 bp NM_000201.2 
ICAM-1 
qRev 
intercellular adhesion 
molecule 1 
CCT CTG GCT TCG 
TCA GAA TCA 
190 bp NM_000201.2 
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primer 
name 
gene name primer sequence PCR 
product 
size 
NCBI 
reference 
sequence 
IL-8 qFwd interleukin 8 CTC TTG GCA GCC 
TTC CTG ATT 
147 bp NM_000584.3 
IL-8 qRev interleukin 8 ACT CTC AAT CAC 
TCT CAG TTCT 
147 bp NM_000584.3 
PECAM-1 
qFwd 
platelet/ endothelial cell 
adhesion molecule 1 
CAA CGA GAA AAT 
GTC AGA 
259 bp NM_000442.5 
PECAM-1 
qRev 
platelet/ endothelial cell 
adhesion molecule 1 
GGA GCC TTC CGT 
TCT AGAGT 
259 bp NM_000442.5 
VCAM-1 
qFwd 
vascular cell adhesion 
molecule 1 
GCT GCT CAG ATT 
GGA GAC TCA  
100 bp NM_001078.3 
VCAM-1 
qRev  
vascular cell adhesion 
molecule 1 
CGC TCA GAG 
GGC TGT CTATC 
100 bp NM_001078.3 
18SrRNA 
qFwd 
18S ribosomal RNA 
rDNA 
GGT TCG AAGACG 
ATC AGA TACC 
344 bp NR_003286.1 
18SrRNA 
qRev 
18S ribosomal RNA 
rDNA 
TCG TTC GTT ATC 
GGA ATT AACC 
344 bp NR_003286.1 
Table 2.2. Primers for real-time PCR. The 18S rRNA primers were established in the 
laboratory as qPCR reference for endothelial cells and were designed with Primer 3 
software [83]. The sequences for PECAM-1 were taken from Kirschbaum et al. [84], and 
the remaining primer sequences were taken from Tersteeg et al [85]. Primers were 
ordered from Eurofins Genomics (Ebersberg). 
 
2.2. Preparation of polymer and chemical activation 
Work on this thesis was conducted in conjunction with another doctoral thesis [51] that was 
carried out in the chemistry group of the Institut für Biomedizinische Technik at the 
University of Rostock. All methods relating to the chemical preparation of the examined 
materials that were performed by chemists have therefore been separated from the 
material and methods section and can be found in the appendix.  
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2.3. Electron microscopy of PCL surface modifications 
PCL samples were imaged without the need for precoating in an XL-30 field emission 
environmental scanning electron microscope (Philips, Eindhoven, NL) at 1.07-1.33 mbar 
and high voltage of up to 10 kV.  
 
2.4.  Isolation of endothelial cells 
Umbilical cords were obtained from donors with their informed consent (University of 
Rostock ethics committee approved protocols II HV 09/2000 and II HV 38/2004). HUVECs 
were isolated through enzymatic digestion protocol (10 min with 0.05% collagenase II at 
37°C, rinsing, 10 min centrifugation at 50 g) and identified by their characteristic polygonal 
shape and cobblestone growth pattern in vitro. Then they were cultured as primary cells in 
MCDB131-based optimized endothelial cell medium (see below) at 37°C, 95% humidity 
and 5% CO2 through to passage 6. MCDB131 base medium was from PAN Biotech 
(Aidenbach). 
 
2.5. Endothelial cell culture 
HUVECs were cultured as primary cells in MCDB131-based optimized endothelial cell 
medium (0.1 ml/ml fetal calf serum, lowered to 0.025 ml/ml during VEGF stimulation, 0.1 
ng/ml EGF, 1 ng/ml bFGF, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine; 
different concentrations were applied during the series of optimization experiments) at 
37°C, 95% humidity and 5% CO2 through to passage 6. Human coronary artery endothelial 
cells (HCAECs) were cultured in endothelial cell medium (PromoCell). Cells were passaged 
as follows: wash cells for 15 s with 3 ml 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), remove HEPES, add 2 ml of trypsin, monitor cell detachment at room 
temperature under a TS100 light microscope (Nikon, Düsseldorf), add 4 ml trypsin 
neutralising solution (TNS), transfer cells into a 15 ml tube, pellet in a Universal 32 R 
centrifuge (Andreas Hettich GmbH & Co. KG, Tuttlingen) at 1100 rpm for 3 min, resuspend 
cells in 6 ml medium. Under the light microscope, cells were counted in a hemocytometer. 
Cells were seeded in 75 cm2 tissue culture flasks at a density of about 1×104 cells/cm2. 
In experiments with cell cycle arrest, the endothelial cells were starved for 24 h in arresting 
medium (0.005 ml/ml fetal calf serum, 0.1 ng/ml EGF, 1 ng/ml bFGF, 100 U/ml penicillin, 
100 µg/ml streptomycin, 2 mM L-glutamine).  
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2.6. VEGF stimulation of HUVECs and HCAECs 
VEGF165 was purchased from Pepro Tech Inc. (Rocky Hill, USA) and dissolved in sterile 
water to prepare a stock solution of 0.1 mg/ml. For stimulation of primary cells, working 
solutions were prepared in optimized endothelial cell medium. Endothelial cells were 
cultured until passage 3 and 24 h before stimulation, their cell cycle was reversibly arrested 
by depletion of growth factors and fetal calf serum from the culture medium. For direct 
VEGF stimulation, the culture medium was deprived of a number of growth factors and 
additives, including epidermal growth factor, basic fibroblast growth factor, and an 
‘endothelial cell growth supplement’ (ECGS) of unknown content by a commercial provider 
(PromoCell). In the case of qPCR analysis (see sections 2.10-2.12), VEGF stimulation was 
for 24 h. One passage prior to the polymer tests, their response to VEGF was tested as 
follows: 3000 cells were seeded per well in a 96-well microtiter plate (Greiner BIO-ONE, 
Frickenhausen) and then stimulated for 96 h with 0.5, 1, 10, 25, 50,75 or 100 ng/ml VEGF. 
After 96 h, cell viability and proliferation was quantified. 
 
2.7. Biocompatibility assays 
All experiments included untreated cells as a control, polystyrene as control substrate, and 
a cell treatment control with 10-4 M tetraethylthiuram disulfide (TETD). This cytotoxic 
substance was used to demonstrate cell susceptibility to poisoning, as it drastically reduces 
the readouts in biocompatibility assays. Where polymer films were involved, circular discs 
(Ø = 6 mm; in the case of subsequent qPCR analysis: Ø = 10 mm) were punched, washed 
three times and fastened at the bottom of microtiter wells with the aid of teflon rings. These 
held the samples in place while allowing cells to be seeded and grown on the disc surface, 
i.e. the rings served to standardize growth conditions. To exclude potential bias introduced 
by the presence of the rings during the biocompatibility assay measurements, identically 
treated cells were allowed to adhere to the films in the presence of slightly differently 
shaped teflon rings and subjected to the standard measurements. Depending on the wall 
thickness of the rings, all measurements were skewed towards higher absolute readings 
compared to those without the rings (appendix A.6). Therefore, in obtaining the data 
presented here, all teflon rings had to be removed before the actual tests, or the CQB 
medium was transferred onto a fresh microplate before fluorescence readings. 
As both PCL films and microwells are circular, the cell density is calculated by the following 
formula: D=π/π×r², with n=number of cells seeded per well and r=substrate radius. 
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2.7.1. Cell viability assay 
Cell viability was determined with the CellQuanti-Blue (CQB) assay (BioAssay Systems, 
Hayward, USA), a test detecting metabolic activity in living cells. Specifically, this assay 
measures the activity of intracellular reductases reducing resazurin substrate to resorufin. 
Cells were seeded in a 96-well microtiter plate. CQB medium was added to each well 
including the blank wells (wells without cells) after 96 h incubation, and the plates were 
returned to the incubator at 37°C for 2 h. Fluorescence signals were measured in a Fluostar 
Optima plate reader (BMG Labtech, Ortenberg) using an excitation wavelength of 542 nm 
and an emission wavelength of 590 nm. The fluorescence intensity obtained is directly 
dependent on the activity of the cells. 
2.7.2. Cell proliferation assay 
For measuring cell proliferation, 5-bromo-2'-deoxyuridine (BrdU) was added to the cells 18 
h prior to testing and the incubation at 37°C continued. Then the medium was removed, cell 
fixation solution (200 µl per well) from the chemiluminescent BrdU-based cell proliferation 
assay (Roche Diagnostics GmbH, Mannheim) was added to the cells for 30 min at room 
temperature, then removed. Anti-BrdU antibody (HRP-conjugated) was diluted 1:100 and 
added to each well (100 µl) before a 90 min incubation period at room temperature. After 
removing the antibody solution, the samples were washed three times, and 100 µl substrate 
were added to each well, followed by 5 min shaking at 500 rpm. Luminescence was read in 
the Fluostar Optima plate reader within 10 min of adding the substrate. 
2.7.3. Eluate test  
Untreated plain PCL, PCL/HMDA, PCL/MDI/NH3, PCL/O2 plasma and thermanox as 
reference polymer were tested for their effect on HUVEC growth. The test materials were 
eluted (6 cm2/ml) at 37°C in serum-free HUVEC growth medium for 24 h with vigorous 
shaking according to DIN 10993-12. 2000 cells per well were seeded and allowed to 
adhere to the microtiter plate for 24 h. Then a dilution series of the eluates was prepared 
(down to 1:32), the growth medium was removed from the cells and replaced with eluate in 
the different dilutions. HUVECs were incubated with the respective eluates for 48 h under 
standard culture conditions and then cell viability and proliferation was measured as 
described above. 
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2.8. ECM protein precoating 
Fibronectin (cat.no. F2006), collagen I (cat.no. C7661) and laminin (cat.no. L2020) were all 
purchased from Sigma-Aldrich. Stock solution (1 mg/ml) was diluted in cell culture medium 
directly prior to coating. PCL films (6 mm discs), thermanox discs (6 mm) and polystyrene 
wells of 96-well microtiter plates were all treated equally for coating purposes, with 40 µl 
protein solution per microwell. Pure culture medium was used for non-coating controls. 
Coating conditions were 60 min at 37°C, followed by aspiration of the coating solution and 
two 10 min washes with sterile water. Homogeneity of the protein layer was confirmed by 
fluorescent labeling of amino groups and subsequent CLSM. 
 
2.9. Confocal laser scanning microscopy 
In parallel to biocompatibility testing, identically treated samples were stained using the 
Live/Dead viability/cytotoxicity kit (Invitrogen). For Live/Dead staining the reagents calcein 
AM and ethidium homodimer were diluted (1:800 and 1:400, respectively) in phosphate 
buffered saline (PBS, pH 7.4), mixed and 200 µl of the mixture was applied to the cells, 
followed by incubation at room temperature for one hour. Calcein AM is a precursor 
molecule that is taken up by viable cells and cleaved by intracellular esterases to form the 
fluorescent green cytosolic marker calcein. Ethidum homodimer is a fluorescent dye that 
cannot permeate intact cell membranes and therefore accumulates in non-viable cells. 
There its high affinity for DNA causes the labeling of these cells via emission of red 
fluorescent light. For phalloidin staining the cells were fixed in 4% formalin and incubated 
for 30 minutes with fluorescein isothiocyanate (FITC) labeled phalloidin (1 µg/ml) at room 
temperature. Phalloidin binds to actin filaments and therefore stains the cytoskeleton. 
Confocal micrographs were obtained using a Fluoview FV1000 (Olympus, Hamburg) 
system.  
 
2.10. Isolation and purification of RNA 
For the purpose of mRNA expression analysis, endothelial cells were seeded onto 10 mm 
polymer discs at 15,000 cells/cm2 in a 48-well microtiter plate and allowed to adhere for 24 
h. Then a 24 h stimulation period with 25 ng/ml VEGF followed. After these two days of 
growth, the medium was drained from the cells, 300 µl Trizol reagent were added to the 
wells containing substrate and cells, and the suspension was collected in 2 ml RNase-free 
reaction tubes. After adding 30 µl chloroform, the samples were homogenized by thorough 
shaking for 1 min, then incubated for 5 min at room temperature. After 5 min, the mix was 
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centrifuged at 4°C and 12,000 g for 5 min, yielding three separated phases. The aqueous 
upper phase containing RNA was transferred to a new RNase-free microtube and another 
200 µl Trizol (Invitrogen) and 20 µl chloroform were added. After vigorous shaking and 3 
minutes incubation at room temperature, the samples were centrifuged again at 12,000 g 
for 2 min. Then the aqueous upper phase was transferred to a new RNase-free microtube 
and an equal volume of 70% ethanol was added. After thorough shaking, this mix was 
transferred onto an RNeasy spin column (Qiagen, Hilden), then centrifuged at 12,000 g for 
15 s. The flow-through was discarded and 350 µl wash buffer RW1 (Qiagen) was pipetted 
onto the column, which was then centrifuged at 12,000 g for 15 s. The flow-through was 
again discarded. To exclude DNA contamination of the RNA, the sample was digested with 
DNase I for 15 min at room temperature. Again 350 µl wash buffer RW1 was applied to the 
spin column, and after 15 s centrifuging at 12,000 g the flow-through was discarded. The 
column was inserted into a new RNase-free collection tube, 500 µl wash buffer RPE 
(Qiagen) were applied, and after 15 s centrifuging at 12,000 g the flow-through was 
discarded. After adding another 500 µl buffer RPE, the samples were centrifuged at 12,000 
g for 2 min and after discarding the flow-through again for 1 min, to dry the column. Finally 
the purified RNA was eluted with 30 µl RNase free water and 2× centrifugation at 12,000 g 
for 1 min. RNA concentration was measured with an Ultrospec 2000 photometer and RNA 
quality assessed by the ratio (absorbance at 260 nm): (absorbance at 280 nm). 
 
2.11. Reverse Transcriptase-PCR 
RNA was transcribed into cDNA using the RevertAid First Strand cDNA Synthesis Kit 
(Thermo Fisher Scientific) as follows: total RNA (200 ng per sample) was first primed with 
275 ng of random hexamers at 70°C for 5 min. After the addition of first strand buffer (final 
concentration 50 mM Tris-HCl, 50 mM KCl, 4 mM MgCl2, 10 mM DTT), ribonuclease 
inhibitor (0.5 U/µl) and dNTPs (1 mM), a 5 min incubation at room temperature was 
followed by the addition of M-MuLV reverse transcriptase (2 U/µl of final reaction volume). 
Reverse transcription was performed for 90 min at 37°C, followed by 10 min heat 
inactivation of the enzyme at 70°C. A control of total RNA in the absence of reverse 
transcriptase was included to exclude genomic contamination of the RNA samples. The 
resulting cDNA was diluted 1:7 in sterile water and stored at -20°C. 
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2.12. Quantitative PCR 
In twintec 96-well source plates (Eppendorf), 7.5 µl Platinum SYBR Green qPCR Supermix 
containing Thermus brockianus DNA polymerase (Invitrogen), 3.0 µl primer mix (containing 
1 pmol/µl each of fwd and rev primers) and 4.5 µl diluted cDNAs were pipetted per well. No-
template controls were also performed to ensure specificity of the PCR amplification. The 
plates were sealed with adhesive optical film (BZO Seal Film, Biozym Scientific GmbH). In 
an Eppendorf Mastercycler, PCRs were done as 15 µl reactions with the following cycle 
conditions: 15 min initial denaturation at 95°C, 40 PCR cycles (12 s denaturation at 94°C, 
25 s annealing at 56°C, 30 s extension at 72°C), 5 min final extension at 72°C, followed by 
15 s at 72°C, a 20 min ramp to 95°C, 15 s at 95°C and 1 min at 20°C for melting curve 
analysis of the PCR products (figure 2.1). Results were quality controlled (figures 2.1 and 
2.2) with realplex software (Eppendorf) and analysed with the 2-∆∆Ct method [86]. 
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Figure 2.1.  
Melting curve analysis 
of HCAEC/PCL/NH3 
plasma/fibronectin (C7) 
qPCR on IL-8 (blue), 
PECAM-1 (purple), 
ICAM-1 (brown) and 
eNOS (green) showing 
specificity of PCR 
products. 
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2.13. Statistical analysis 
Data were analyzed using the SPSS statistical package 21.0 (SPSS Inc., Chicago, Illinois, 
USA). Descriptive statistics were computed for continuous and categorical variables. The 
statistics computed included mean and standard deviations (SD) of continuous variables 
and are presented as mean±SD and percentage frequencies of categorical factors. For cell 
culture experiments, means and standard deviations were calculated from 8 individual 
measurements per condition. For differences between individual values, the square root of 
the sum of the squares of the two individual SD values yielded the SD of the difference. For 
normalization purposes, the raw data were standardized prior to analysis as follows: the 
microtiter plate-specific mean of the blank values (cell culture medium only) was divided by 
a ratio R, with R = (mean of untreated control cells on polystyrene) : (mean of blanks). This 
normalized blank value was then subtracted from all raw data of each microtiter plate, such 
that values from individual experiments became comparable. A two-directional t test was 
also used for statistical analysis. Generally, to evaluate statistical significance between 
groups, a two-way or one-way analysis of variance (ANOVA) was used to examine the 
influence of categorical, independent variables on one dependent variable. All p-values 
<0.05 which resulted from two-sided statistical tests were considered to be statistically 
significant. Over the series of PCL testing with HUVECs from three different donors, a 
univariate analysis of variance was used to evaluate statistical significance. 
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Figure 2.2. 
 Amplification plots of cDNA 
from HUVECs grown on 
PCL/O2 plasma and 
stimulated with VEGF. PCR 
on 18S rRNA (grey), ICAM-1 
(olive), PECAM-1 (blue) and 
IL-8 (green) showing 
reproducibility of single-well 
reactions. 
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2.13.1. Nalimov test for outliers 
The Nalimov test is particularly suited to test for outliers in small to medium sample sizes 
[87]. It is based upon the assumption of normality. A particular value x₁ is identified as an 
outlier if the statistic q  
 
....  mean of all values (incl. the value x ₁) 
s .... standard deviation of all values 
n .... number of values 
exceeds the critical threshold qcrit for a given level of significance. If the calculated value of 
q is greater than the critical threshold, then the corresponding data value x₁ is regarded to 
be an outlier. The threshold values and corresponding levels of significance are listed in 
appendix table A1. 
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3. Results 
3.1. Morphology of the polymer samples 
Plain PCL presented with an overall wavy and cobblestone-like surface under the 
environmental scanning electron microscope (figure 3.1a). Electrospun PCL showed a 
pattern of irregularly interwoven PCL fibers that are approximately 5 µm wide (figure 3.1b). 
PCL etching with NaOH resulted in surface roughening with elongated cracks and cavities 
(figure 3.1c). Salt leaching produced cavities in the polymer that are 8 to 30 µm wide and 
make for a highly irregular surface structure (figure 3.1d). Neither chemical activation with 
O2 plasma (figure 3.1e) nor with NH3 plasma (figure 3.1f) nor with 
aminopropyltriethoxysilane (APTES, figure 3.1g) nor with hexane-1,6-diamine (HMDA, 
figure 3.1h) resulted in morphological changes of the plain polymer surface. The surface 
reaction of PCL with 4,4′-methylenebis(phenyl-isocyanate) (MDI) produced very fine cracks 
of up to 300 µm in length in the otherwise preserved wavy surface (figure 3.1i). All changes 
to the polymer surface, including manipulation of the morphology, wet chemical and plasma 
chemical activation, were verified by contact angle measurement. The corresponding figure 
can be found in the appendix. 
 
Figure 3.1. ESEM micrographs of the morphology of the variously 
functionalized PCL surfaces. Magnification 200× (a-c) and 
100× (d-i), respectively. 
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3.2. Biocompatibility of functionalized polymers 
When biomaterials are assessed for their biocompatibility, a fairly obvious prerequisite is 
that they should not possess any cytotoxic potential. In order to test for possible cytotoxic 
effects of the polymer, Human umbilical vein endothelial cells (HUVECs) were subjected to 
eluates from PCL and three exemplary modifications. Two reference materials were used 
here: thermanox (Thermo Scientific), a proprietary polymer that is highly resistant to most 
chemicals and treated for optimum cell attachment and growth in vitro, and polystyrene. 
Relative cell viability decreased with increasing concentration of the eluate. When 
compared to polystyrene, cell viability on differentially modified PCL fell below the reference 
line only in the samples exposed to the undiluted eluates (figure 3.2a), a situation that 
would not occur under physiological circumstances with constant blood flow. Twelve out of 
twenty diluted PCL eluates even led to significantly higher HUVEC viability than the pure 
culture medium. HUVECs on plain PCL as well as on O2 plasma activated PCL showed 
lower proliferation rates compared to control cells on polystyrene (figure 3.2b). However, 
when the various PCL eluates were diluted, all HUVECs incubated in those samples 
showed proliferation rates that were significantly higher (p<0.01) than the rate seen in cells 
subjected to the undiluted thermanox eluate. 
As can be seen in figure 3.2c and d, the various PCL eluates do not compromise HUVECs 
as much as undiluted thermanox eluate in terms of biocompatibility, as measured in both 
proliferation rate and viability of HUVECs growing in them. The highest viability of the cells 
was seen on plain PCL, but the differences between the individual PCL eluates were not 
significant. The respective values of the culture medium/polystyrene control fell in the same 
range as the cells incubated with the most diluted eluates, and on PCL/HMDA the cells 
incubated with up to 50% eluate concentration even showed higher relative viability and 
proliferation than the control cells. Of the PCL modifications, the oxygen plasma-activated 
form (PCL/O2 plasma) was the one giving the lowest values for both viability and 
proliferation. None of these differences reached statisitical significance, whereas all 
dilutions of the different PCL eluates produced significantly higher viability and proliferation 
rates in HUVECs than thermanox as the reference material. Thus, regardless of surface 
modification, obvious cytotoxic properties of PCL could be excluded. 
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Figure 3.2. Biocompatibility of PCL and three functionalized varieties. The samples were eluted in 
cell culture medium for 24 h and then, in a dilution series, applied to pre-seeded 
HUVECs for 48 h before viability and proliferation testing. The reference (100%) used 
is polystyrene (for a and b) and undiluted thermanox polymer eluate (for c and d), 
respectively. 
 
3.3. Optimization of VEGF stimulation 
Primary endothelial cells can be isolated with relative ease and can then be cultured in 
vitro. Depending on the scientific question, the parameters for cell culture must be adapted. 
Here, the media composition, seeding density, number of passages, incubation time, cell 
cycle arrest and concentration of stimulating factors all had to be optimized before 
experiments on biomaterials could be conducted. 
This part of the thesis is aimed at establishing a reliable in vitro model for the 
endothelialization of vascular implants, and then using this model to characterize the 
response of human primary endothelial cells on numerous PCL modifications in terms of 
biocompatibility, cell adhesion and morphology, and changes in gene expression. 
3.3.1. Parameter 1: media composition  
Ingredients of cell culture medium can have potent and potentially biasing effects on the 
behavior of cells and therefore need to be scrupulously controlled. The initial culture 
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medium composition contained a number of growth factors and additives, including 
epidermal growth factor, basic fibroblast growth factor, and an ‘endothelial cell growth 
supplement’ (ECGS) of unknown content by a commercial provider. HUVECs from that 
provider as well as self-isolated ones were cultured in the recommended medium for up to 
5 days. The application of VEGF to endothelial cells incubated for 1 day and for 5 days with 
this complete medium yielded no stimulation of their viability or proliferation, regardless of 
VEGF concentration and cell source (figure 3.3). 
 
Figure 3.3. Effect of VEGF on HUVECs grown for 5 days in endothelial cell culture medium 
containing 0.1 ng/ml EGF, 1 ng/ml bFG and 4% endothelial cell growth supplement. 
 
This result pointed to a probable masking of the stimulatory effect of the specific growth 
factor in the presence of other growth factors. Consequently, the cell culture medium was 
deprived of those factors and the endothelial cells stimulated with VEGF alone. As a result, 
the relative viability and proliferation of HUVECs were found to be stimulated (see figures 
3.4 to 3.7). 
As the complete medium contained 10% fetal calf serum, an experiment was done to test 
the effect of substantially lowered serum content. The comparison was between HUVECs 
growing in endothelial cell culture medium containing 2.5% fetal calf serum (in accordance 
with [67]) and HUVECs growing in that medium without any serum. Figure 3.4 shows that 
serum is required for the stimulatory effect of VEGF to take hold, and that 2.5% serum is 
sufficient to achieve significant stimulation at two different doses of VEGF. It also shows 
that in the absence of serum the viability of HUVECs decreases with time. 
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Figure 3.4. Impact of serum content and VEGF on relative 
viability of HUVECs over three days. Reference 
(100%; dashed line) is HUVECs viability in 
medium with 2.5% FCS in the absence of VEGF 
(measured in 24 h intervals). 
 
3.3.2. Parameter 2: number of cell passages 
It is known that primary cells tend to lose certain characteristics of their phenotype over 
time, i.e. after undergoing a number of mitotic cell divisions in culture [10]. Most 
researchers working with endothelial cells restrict experiments to <10 passages. In order to 
get information on the impact of this methodological factor, direct comparisons of different 
passages of cells from the same batch were performed. The responsiveness of HUVECs to 
VEGF generally decreased as the number of passages increased (figure 3.5). For cell 
viability, these differences were statistically significant at 1, 5 and 50 ng/ml VEGF. For 
relative proliferation rates, these differences were significant at 25 and 100 ng/ml VEGF, 
with VEGF stimulation at 25 ng/ml VEGF the only instance where relative proliferation in 
passage 7 was higher than in passage 3. As a consequence of these results, all 
experiments thereafter were performed with cells in passages 3 to 6. 
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Figure 3.5. Extent of VEGF responsiveness varies with cell passage. Cell viability (a) and 
proliferation rates (b) of same-batch HUVECs in passages 3 and 7 after 72 h of 
stimulation with VEGF relative to unstimulated control. Asterisks denote statistical 
significance of difference between passage numbers (* p<0.05, ** p<0.01). 
 
3.3.3. Parameter 3: VEGF concentration, time and duration of stimulation 
Once cell growth is stimulated, the difference to an unstimulated control is expected to 
increase with time. Therefore the cell response to VEGF was monitored in 24 h intervals up 
to 96 h. To test for a possible concentration-dependent effect, eight different concentrations 
of VEGF were included in the experiments. The first set of experiments involved testing 
VEGF concentrations from 0.5 ng/ml to 100 ng/ml. Moreover, the VEGF stimulus was 
applied at two different time points: 1. immediately after cell seeding and 2. 24 h after cell 
seeding. Figures 3.6 and 3.7 show that after 24 h of stimulation, there were no significant 
differences between stimulated and unstimulated cells (there was no separate 
measurement of the cells that first received VEGF at this time point). After 48 h, the 
differences were significant at all eight concentrations, regardless of the time of VEGF 
application. Figure 3.6 shows how the HUVEC response to VEGF differed between the two 
groups: the relative viability of the immediately stimulated cells reached 116.9±8.7% (at 0.5 
ng/ml) to 172.2±12.9% (at 5 ng/ml), and in the cells receiving the late stimulus viability 
increased between 115.8±5.5% (at 0.5 ng/ml) and 148.1±12.5% (at 5 ng/ml) compared to 
the unstimulated control cells. The extent of stimulation in both groups increased overall 
with dose and time, and reached 400.8±17.8% (with 75 ng/ml VEGF immediately after cell 
seeding; figure 3.6a) and 378.3±30.1% (with 75 ng/ml VEGF 24 h after cell seeding; figure 
3.6b) at 96 h after seeding.  
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Figure 3.6. Effect of VEGF concentration and stimulation time on the viability of HUVECs. Cells 
were seeded, stimulated with VEGF (a) immediately after seeding or (b) 24 h after 
seeding at the concentrations indicated and incubated in 24 h intervals for up to 96 h 
along with non-stimulated controls (100%) before viability testing. Another control 
was subjected to 10
-4
 M TETD to demonstrate susceptibility of the cells to cytotoxic 
substances. 
 
In addition, cell proliferation was measured under the same conditions, and the results 
(figure 3.7) showed a high degree of similarity to the viability testing (figure 3.6). When 
VEGF was administered immediately upon cell seeding, no significant stimulatory effect on 
cell proliferation could be seen 24 h later (maximum of 108.9±5.8% relative proliferation at 
5 ng/ml VEGF; figure 3.7a) at all 8 concentrations. When the growth factor was given with a 
24 h delay (figure 3.7b), the stimulation on the second day was slightly less than with those 
cells that had been exposed to VEGF for the whole 48 h period, but in both cases the 
differences to the control cells were highly significant (p<0.01) at all 8 VEGF 
concentrations. On the third day, the VEGF effect on the cells with late VEGF 
administration was slightly higher than on those with early VEGF administration (e.g. 
250.6±14.5% vs 241.8±14.5% at 100 ng/ml). The outlying value at 10 ng/ml in the second 
group (180.5±79.6%, figure 3.7b) was in all likelihood due to experimental error, for it was 
the only result from 48 h to 96 h cell growth with a p-value larger than 0.01 in terms of 
difference to the unstimulated control. Its true value is probably at the upper end of the 
standard deviation and thus closer to the 221.3±14.0% relative viability measured in the 
immediately stimulated cells after 72 h. At the 96 h time point after cell seeding, the 
differences in proliferation rate between the two cell sets virtually disappeared, reaching up 
to 446.0±22.7% (VEGF directly after cell seeding, at 75 ng/ml; figure 3.7a) and 
441.1±30.0% (VEGF after 24 h, at 50 ng/ml; figure 3.7b) of the unstimulated control, 
respectively.  
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Figure 3.7. Effect of VEGF concentration and stimulation time on the proliferation of HUVECs. Cells 
were seeded, stimulated with VEGF (a) directly or (b) after 24 h at the concentrations 
indicated and incubated in 24 h intervals for up to 96 h along with non-stimulated 
controls (100%) before proliferation testing. Another control was subjected to 10
-4
 M 
TETD to demonstrate susceptibility of the cells to cytotoxic substances. 
 
There was virtually no stimulation seen at the 24 h incubation time point, and this was true 
for both cell viability and proliferation. From 48 h onwards, the stimulatory effect leveled off 
around 50 ng/ml and sometimes was slightly reduced again at the maximum VEGF 
concentration (100 ng/ml). While marked stimulation generally could be achieved with 5 
ng/ml, the positive correlation of VEGF dose and relative proliferation tended to drop off at 
all timepoints at the highest doses (>50 ng/ml). On the other hand, very distinct differences 
in the extent of stimulation from one day to the next could already be seen at 10 ng/ml. The 
series of experiments showed a concentration of 25 ng/ml to be effective for reliable and 
reproducible stimulation of HUVECs (figures 3.6 and 3.7), For reliable and reproducible 
stimulation of HUVECs, the concentration of 25 ng/ml was used as the standard in all 
subsequent experiments, with stimulation of the cells immediately after seeding and 96 h as 
the standard incubation time. 
 
3.3.4. Parameter 4: initial cell density 
A range of different cell seeding densities was sampled to test which one is optimal for 
VEGF stimulation, as seeding density is known to crucially affect results of endothelial cell 
testing in vitro [88]. At first, the cells were tested in the absence of VEGF. There was a 
linear correlation: the more cells were seeded, the higher their measured viability and 
proliferation rates were after 5 days (figure 3.8). When standardized to the lowest number 
of seeded cells (11,000/cm2), the relative readings for 21,000 cells/cm2 reached 
143.9±5.0% (viability) and 268.5±13.2% (proliferation). With the exception of relative 
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proliferation at 14,000 cells/cm2 (p=0.08), all differences to the minimum density were 
highly significant (p<0.0025). 
 
Figure 3.8. Effect of seeding density of HUVECs on magnitude of 
fluorescence (viability) and luminescence (proliferation) 
readings in routine biocompatibility assays. Shown is the 
relative intensity compared to 11,000 cells/cm
2
 (100%) after 
5 days of growth. Asterisks denote statistical significance of 
difference to that 100% control (* p<0.05, ** p<0.01). 
In the next step, an experiment was set up to test whether initial cell density had an impact 
on VEGF responsiveness of HUVECs. As the experiments were done over a period of five 
days, it had to be ensured that the cells did not reach confluence, a state where contact 
inhibition comes into play and a growth factor can no longer stimulate cell growth. Cell 
viability and proliferation rate were separately measured at the four different densities and 
as expected, the relative stimulatory effect of VEGF decreased with increasing cell seeding 
density (figure 3.9). At 21,000 cells/cm2, the effect upon cell proliferation disappeared 
altogether (figure 3.9b) At 11,000 cells/cm2, the cells’ viability increased to 176.2±7.4% in 
the presence of VEGF compared to the unstimulated control, whereas at 21,000 cells/cm2 it 
only reached 150.9±6.6%. (The comparison between stimulated and unstimulated cells had 
to be done separately for each cell density, because of the confounding effect of seeding 
density described above.) 
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Figure 3.9. Effect of seeding density of HUVECs on magnitude of VEGF stimulation in terms of a) 
cell viability and b) proliferation rate readings in routine biocompatibility assays. Shown 
is the relative stimulation compared to the unstimulated control (set at 100% for each 
cell density) after 5 days. Asterisks denote statistical significance of VEGF effect at the 
respective seeding density (* p<0.05, ** p<0.01). 
 
Because of the oppositional factors seeding density and relative stimulatory effect, a 
compromise needed to be found where enough cells grew to give fluorescence readings 
well above background levels, yet the density was not so high as to mask the growth factor 
induced stimulation. This was set at 11,000 cells/cm2.  
 
3.3.5. Parameter 5: cell cycle arrest 
Arresting the cell cycle is a commonly used manipulation of cells in vitro that harmonizes 
them in a specific stage of the cell cycle (G0, G1 or G2 phase). This arrest is transient and 
can be induced, for example, by medium depletion [89]. While only cells in G phase 
respond to growth inhibition, the remaining cells will complete the cell cycle but not enter a 
second one [90]. After release of cellular arrest, the cells generally spontaneously revert 
from the arrested state and proceed with the cell cycle [91]. Here cell cycle arrest was 
achieved by nutrient depletion for 24 h. Subsequently the cells were stimulated with 25 
ng/ml VEGF in medium that was rich in nutrients but otherwise deprived of mitogenic 
factors (see section 2.10). Figure 3.10 illustrates that at identical seeding densities, cell 
cycle arrest prior to VEGF stimulation enhances the VEGF responsiveness of HUVECs. 
While for relative viability the effect was detected at all seeding densities, it was statistically 
significant only at 11,000 cells/cm2 (192% vs 176% stimulation) and 21,000 cells/cm2 (201% 
vs 151% stimulation). For relative cell proliferation, the enhanced VEGF response through 
cell cycle arrest was much more pronounced and highly significant (p<0.01) at all seeding 
densities, reaching a maximum of 863% stimulation (compared to 169% at the same 
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seeding density without cell cycle arrest) at the lowest initial cell density (11,000 cells/cm2), 
confirming the previous results on magnitude of VEGF stimulation (compare figure 3.9). 
 
Figure 3.10. Cell cycle arrest prior to stimulation greatly enhances the effect of VEGF on HUVECs. 
Shown is (a) the relative viability and (b) relative proliferation rate compared to the 
unstimulated control (set at 100% for each cell density and separately for ‘not 
arrested’ and ‘arrested’). Cells were seeded 24 h before VEGF stimulation, which 
then lasted 96 h. Arrested cells had been seeded and incubated in arresting medium 
for 24 h. Asterisks denote statistical significance of difference with/without cell cycle 
arrest (* p<0.05, ** p<0.01). 
 
3.4. Reproducibility of VEGF response 
The first tests of the effect of VEGF on HUVECs with three different reference materials 
produced a wide range of relative stimulation (figure 3.11). Of 64 individual measurements 
of cell viability in total, 53 (i.e. 82.8%) yielded a VEGF-induced stimulation of more than 
130% (arbitrary threshold) compared to unstimulated cells. The degree of variability is 
independent of the substrate presented to the cells, but failure of stimulation (i.e. <100% 
relative viability) is most frequently associated with thermanox (4.7% of tests on this 
substrate). In contrast, 91% of all measurements on polystyrene and 95% of those on glass 
lay above the 130% threshold. This threshold was chosen to exclude random deviations 
and ensure that the detected range of responses was due to biological variability. 
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Figure 3.11. Scatter plot of 64 viability measurements with VEGF-stimulated 
HUVECs from 11 different donors growing on 3 different 
reference substrates. VEGF was given immediately after cell 
seeding at 25 ng/ml. Shown is only the mean viability of cells 
relative to the unstimulated control, without standard deviation. 
In order to ascertain that all primary cells grown on polymers were susceptible to VEGF 
stimulation, from then on every batch of HUVECS was routinely pre-stimulated on glass, 
thermanox and polystyrene. Figure 3.12 shows five representative examples. The extent of 
stimulation varied considerably with cell donor and VEGF concentration, but had to exceed 
said threshold for polymer experiments to proceed (leading to the exclusion of batch 5 in 
figure 3.12, for example). 
 
Figure 3.12. Pre-stimulation of different batches of HUVECs with VEGF. HUVECs at passage 3 
were seeded on polystyrene at 11,000 cells/cm
2
 and stimulated for 96 h with VEGF at 
the concentrations depicted. Shown is (a) their relative viability and (b) proliferation 
rate on polystyrene as compared to the non-stimulated control (set at 100%). 
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3.5. Viability of endothelial cells on PCL 
3.5.1. Influence of PCL morphology on cell adhesion and viability 
An important aspect in implant material selection is whether the morphology of its surface 
has an impact on the viability of cells adhering to it. From the experiments with PCL eluates 
it was already clear that HUVECs adhering to PCL are less viable than on the reference 
material polystyrene (see figure 3.1). Therefore plain PCL was used as the reference in the 
subsequent experiments on the effects of polymer surface modification. While salt leaching 
was the only treatment that allowed a slightly higher viability of both cell types (HUVECs: 
103.5±13.0%, HCAECs: 112.4±17.8% relative to plain PCL), this increase was statistically 
not significant. This can be seen in figure 3.13. 
 
 
Figure 3.13. Relative cell viability of (a) HUVECs and (b) HCAECs after 96 h growth on modified 
PCL surfaces. Plain PCL was used as a reference and thus arbitrarily set at 100%. 
n=3 donors á 8 replicates 
 
3.5.2. Influence of PCL surface activation on cell adhesion and viability 
As the different PCL surface morphologies did not show marked effects on the viability of 
adherent cells, only plain PCL films were used for chemical activation and subsequent 
biocompatibility testing. Cell viability was measured after 96 h in relation to plain PCL. As 
can be seen in figure 3.14, for both cell types surface activation by itself did not greatly 
improve cell viability. For HUVECs, the changes were not significant when compared to 
plain PCL (figure 3.14a), with the values ranging from 80.8±19.8% (MDI/ NH3 activation) to 
129.0±27.0% (NH3 plasma activation). However, the differences in viability of HUVECs 
reached statistical significance when different forms of PCL activation (plasma vs. wet 
chemical) were directly compared. Relative viability on PCL/O2 plasma was significantly 
higher than on PCL/MDI/NH3 and PCL/O2/APTES, while relative viability on PCL/NH3 
plasma was significantly higher than on PCL/MDI/NH3, PCL/O2/APTES and PCL/HMDA.  
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Figure 3.14. Relative cell viability of (a) HUVECs and (b) HCAECs after 96 h growth on activated 
PCL. Plain PCL was used as a reference and thus arbitrarily set at 100%. Asterisks 
denote statistical significance of difference to the reference (* p<0.006). n=3 donors 
á 8 replicates 
 
In the case of HCAECs, the increase in viability on O2 plasma activated PCL (162.0±19.6%; 
p=0.0000000004) and NH3 plasma activated PCL (132.2±34.7%; p=0.0058) was highly 
significant compared to that seen on plain PCL (figure 3.14b). At the same time, HCAEC 
viability on all wet chemically activated forms of PCL was less (PCL/MDI/NH3: 91.5±11.2%, 
PCL/O2/APTES: 94.0±6.9% and PCL/HMDA: 98.3±16.0%) than on plain PCL (100±22.2%). 
By far the highest viability of HCAECs was seen on PCL/O2 plasma. 
3.5.3. VEGF response of endothelial cells on PCL 
When the viability of HUVECs is standardized to that seen on unmodified PCL without 
VEGF, it becomes apparent that alterations of the polymer morphology (figure 3.15) result 
in lower effects of growth factor stimulation than chemical activation (figure 3.16). For 
example, electrospinning of PCL combined with the VEGF stimulus resulted in 
101.6±18.0% viability compared to unstimulated HUVECs on plain PCL (figure 3.15a). Over 
all modifications of the polymer, only treatment with APTES (140.9±6.7%), salt leaching 
(140.4±37.7%), O2 plasma (186.8±56.0%) and NH3 plasma (214.9±86.9%) exceeded the 
extent of VEGF stimulation seen on plain PCL (figure 3.16a). Amongst these surface 
modifications, plasma activation stood out as the method yielding by far the highest VEGF-
induced increase in endothelial cell viability. 
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Figure 3.15. Relative cell viability of a) HUVECs and b) HCAECs after 96 h growth on various PCL 
morphologies with and without VEGF stimulation. Plain PCL was used as a reference 
and thus arbitrarily set at 100%. n=3 donors 
 
For HCAECs, the pattern is very similar, especially with the chemically activated forms of 
PCL. Out of eight different modifications of PCL, five yielded higher VEGF-induced viability 
stimulation of HCAECs than plain PCL (144.6±19.7% relative viability): electrospun PCL 
(148.3±43.2%; figure 3.15b), PCL/O2/APTES (154.4±59.1%), PCL/HMDA (160.5±51.8%), 
PCL/NH3 plasma (164.6±47.5%) and PCL/O2 plasma (256.1±128.6%). 
 
 
Figure 3.16. Relative cell viability of a) HUVECs and b) HCAECs after 96 h growth on activated 
PCL with and without VEGF stimulation. Plain PCL was used as a reference and thus 
arbitrarily set at 100%. n=3 donors 
 
Confocal imaging revealed the stimulatory effect of the growth factor in a more pronounced 
manner than the CQB test. When HUVECs were labeled after 4 days of growth using the 
live/dead stain, their enhanced adhesion on various PCL surfaces became apparent (figure 
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3.17). The largest number of viable cells was seen on NH3 plasma-activated PCL, while on 
the non-chemically activated forms of PCL (electrospinning and salt leaching), a high 
proportion of ethidium dimer stained, i.e.non-viable cells was prominent. Electrospun PCL 
presented with the highest ratio of dead vs. viable cells. Overall, adhesion of HUVECs on 
PCL in the absence of VEGF was poor, but was greatly augmented when VEGF was added 
directly after cell seeding. 
 
 
Figure 3.17.  Confocal laser scanning micrographs of HUVEC attachment to PCL 96 h 
after seeding of 2×10
4
 cells and live/dead staining. For each substrate 
cell adhesion without VEGF is shown on the left, in the presence of 25 
ng/ml VEGF on the right. Scale bar for all images: 200 µm 
 
The general picture of the VEGF effect on HCAECs was very similar to the one on HUVECs 
(figure 3.18). The substrate demonstrating the highest abundance of viable cells by way of 
live/dead staining was polystyrene, while NaOH-etched PCL was the PCL variety 
presenting with the most adherent cells compared to the other forms of PCL. Plasma 
activation of the polymer appeared to convey the highest stimulatory effect of VEGF on 
HCAECs. Again a large proportion of non-viable cells was evident on electrospun PCL. 
This prompted a later change of the staining method to phalloidin-FITC (see section 3.4.2). 
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Figure 3.18. Confocal laser scanning micrographs of HCAEC attachment to PCL 96 h 
after seeding of 2×10
4
 cells and live/dead staining. For each substrate 
cell adhesion without VEGF is shown on the left, in the presence of 25 
ng/ml VEGF on the right. Scale bar for all images: 200 µm 
 
The surface-specific analysis of the VEGF effect on HUVEC viability (figure 3.19a) revealed 
that all modifications of PCL resulted in greater viability of HUVECs adhering to them than 
on plain PCL (27.7±5.8% increase). Univariate analysis of variance showed that the gains 
were significant only for PCL/O2/APTES (p=0.03), PCL/NH3 plasma (p<0.001) and PCL/O2 
plasma (p<0.001). The highest stimulation was again seen on NH3 plasma activated PCL, 
albeit with the highest standard deviation (164.1±55.2%). O2 plasma activation of PCL 
resulted in the second-highest VEGF-induced viability stimulation (160.0±35.0%), while wet 
chemical activation with HMDA yielded the lowest effect (131.0±9.5%). 
Stimulation of viability through VEGF on the individual surfaces was again very similar for 
HCAECs, despite overall larger standard deviations (figure 3.19b). Here the highest 
stimulation was detected on O2 plasma activated PCL (168.1±69.8%) and electrospun PCL 
(168.4±81.7%), while on NH3 plasma activated PCL VEGF led to only moderately 
increased viability (120.4±31.6%), even compared to plain PCL (44.6±19.7% increase). 
With PCL/salt leaching as the only exception, all VEGF-induced increases were statistically 
significant. 
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Figure 3.19. Stimulatory effect of VEGF on viability of (a) HUVECs and (b) 
HCAECs growing on modified PCL. Shown is the mean 
modification-specific effect of the growth factor relative to the 
unstimulated (100%) control on that same modification of PCL. 
Asterisks denote statistical significance of difference with/without 
VEGF on the same substrate. n=3 donors per cell type 
 
3.5.4. Covalent coupling of VEGF to polymer 
Covalent coupling of biomolecules is one important strategy to enhance the biocompatibility 
of polymers. Here 4-star-shaped poly(ε-caprolactone) with terminal acrylate groups (sPCL-
A), a functionalized derivative of PCL [92], was used to couple VEGF, via adsorption and 
via crosslinkers (see appendix A.7). Then cell viability of HUVECs grown for 96 h on this 
substrate was compared to equally treated sPCL-A with VEGF directly added to the culture 
66 
 
medium and without VEGF altogether, so as to give information about the bioactivity of 
soluble vs immobilized VEGF. 
When the growth factor was adsorbed onto the polymer (figure 3.20), the viability of 
HUVECs on plain sPCL-A as well as on sPCL-A/HMDA was significantly higher (56.0±8.6% 
and 53.8±6.6% relative to polystyrene, respectively) with VEGF than without it (46.5±5.8% 
and 45.6±5.0%, respectively). On sPCL-A/O2 plasma the difference in viability was even 
higher, but not significantly so. On all three forms of sPCL-A, it made no significant 
difference whether VEGF was adsorbed onto the polymer or applied in soluble form. 
 
Figure 3.20. Impact of VEGF applied in two different ways on relative viability of 
HUVECs growing on sPCL-A with and without modification. 
Soluble growth factor was added at 25 ng/ml. Reference (100%; 
dashed line) is HUVECs viability on polystyrene in the absence of 
VEGF. Asterisks denote statistical significance of differences 
between bracketed groups (* p<0.05). 
 
When VEGF was covalently coupled to sPCL-A via crosslinkers (figure 3.21), the only 
statistically significant differences were between absence and presence of VEGF. In the 
instance of highest relative viability (with VEGF coupled through the crosslinkers N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide (EDC)/ (NHS) to otherwise unactivated sPCL-A; 
80.0±14.9% viability relative to control HUVECs growing on polystyrene), however, the 
differences were not significant. There also were no statistically significant differences in 
HUVEC viability between the two different ways in which VEGF was presented to the cells 
(soluble vs covalently bound on the polymer). On sPCL-A activated with O2 plasma, the 
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viability of HUVECs was significantly increased (to 63.2±2.0% relative to polystyrene) when 
VEGF was coupled to the polymer through the crosslinker DSC, compared to that on 
identically modified sPCL-A without the addition of VEGF (59.4±2.4% relative to 
polystyrene; p=0.012).  
 
Figure 3.21. Influence of crosslinkers (EDC/NHS or DSC) and covalent coupling 
of VEGF on HUVEC growth on functionalized sPCL-A. Soluble 
growth factor was added at 25 ng/ml. Reference (100%; dashed line) 
is HUVECs viability on polystyrene in the absence of VEGF. 
Asterisks denote statistical significance of differences between 
bracketed groups (* p<0.05, ** p<0.01). 
 
3.5.5. Influence of PCL functionalization with ECM protein 
In order to promote endothelial cell adhesion on the polymer regardless of its surface 
properties, PCL was pre-coated with ECM proteins. For specific information on protein and 
dose, four different matrix proteins were screened at three different concentrations each: 
laminin, collagen type I, fibronectin and gelatin.  
Figure 3.22 shows that uncoated PCL as a substrate for HUVECs compares poorly with 
polystyrene, but cell viability on PCL can be markedly improved by precoating it with 
protein. Gelatin gave the most inconsistent results, with the highest protein concentration (1 
mg/ml) in the PCL coating yielding slightly lower cell viability than in the uncoated state. 
Collagen type I, laminin and fibronectin coats on PCL all cause highly significant increases 
in HUVEC viability at the highest concentration used (100 µg/ml). While this effect is directly 
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dose-dependent for collagen type I and laminin, coating PCL with fibronectin results in 
significantly higher cell viability at all three concentrations. 
  
Figure 3.22.  Relative increase in HUVEC viability on PCL through precoating with matrix proteins. 
Shown is the viability after 4 days of growth on PCL and polystyrene compared to that 
on uncoated polystyrene (0 µg/ml) as reference (100%). Asterisks denote statistical 
significance of differences between uncoated and coated PCL (* p<0.05, ** p<0.01). 
 
The general stimulatory effect of protein precoating on HUVEC growth on PCL was 
confirmed with calcein AM staining and fluorescence microscopy (figure 3.23 and A.8). In 
the case of collagen and laminin, however, the dosage dependence seen in viability testing 
could only be partially confirmed. For fibronectin, the dose-dependent effect on HUVECs 
adhesion on precoated PCL was clearly visible under the fluorescence microscope. 
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Figure 3.23. Fluorescent micrographs of calcein AM stained HUVECs grown for 48 h on PCL 
coated with fibronectin, collagen type I and laminin.  
Scale bar for all images: 500 µm 
 
 
Figure 3.24 shows that, with the exception of the lowest laminin concentration (10 ng/ml), at 
all concentrations tested, fibronectin, collagen I as well as laminin lead to increased cell 
viability after 96 h. 
The highest relative increase was seen with 100 µg/ml laminin, at 182.1±9.4% compared to 
the uncoated PCL control (or from 37.2% to 67.7%, respectively, of uncoated polystyrene). 
In the case of fibronectin, all three concentrations resulted in more than 1.5-fold viability of 
HUVECs compared to their growth on uncoated PCL. The extent of stimulation achieved by 
coating with collagen type I or laminin was dose-dependent, but in the case of 10 µg/ml 
laminin, cell viability remained lower (80.8±12.8%) than on the uncoated control. 
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Figure 3.24. Relative increase in cell viability (HUVECs) through 
coating of PCL with extracellular matrix components. 
HUVECs were seeded immediately after coating PCL 
with the respective proteins and concentrations and 
allowed to adhere for 96 h. Reference (100%; dashed 
line) for relative viability is uncoated PCL. 
 
3.6. Confounding methodological factors 
3.6.1. Problem of proliferation testing on polymer films 
When the biocompatibility assays were done with the cells growing on polymer films, the 
results for viability and cell proliferation did not correlate as they did in the preceding 
experiments on tissue culture plastic. While the viability readings for all forms of PCL were 
within a narrow range (35.9±1.6% to 57.8±4.2%) and all well below the value seen on 
polystyrene (figure 3.25a), proliferation testing of the same cells yielded a very wide range 
of 33.5±15.2% to 643.5±131.4%, with plain PCL, PCL/NaOH above polystyrene and 
PCL/MDI/NH3, PCL/salt leaching and PCL/electrospinning even giving multitudes of the 
reading on the polystyrene reference (figure 3.25b). As the proliferation results could 
neither be aligned with those from the viability assay nor with confocal microscopy, 
methodological bias seemed likely. 
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Figure 3.25. Absence of correlation between (a) viability and (b) 
proliferation testing of the same HUVECs growing on 
modified PCL films. Note the different scales of 
relative stimulation. 
 
To analyse the apparent disparity, the BrdU assay was run on various polymers in the 
absence of cells. To test the possibility that there might be an issue with the anti-BrdU 
antibody unspecifically binding to the polymers, a subset of the samples was subjected to 
the test routine minus the antibody.  
As can be seen in figure 3.26, the readings differed extremely, even in the absence of 
antibody. When normalized to polystyrene, all PCL varieties deviated from that baseline, 
from 105±17% (plain PCL) to 3350±1012% (sPCL-A). The differences were more 
72 
 
pronounced when the antibody was included, with sPCL-A again giving the maximum value 
(6613±2674%). In the presence of anti-BrdU, the only modifications that did not significantly 
differ from polystyrene were PCL/O2 plasma and PCL/O2/APTES. 
 
Figure 3.26. Results of BrdU testing on different varieties of PCL films in the 
absence of cells. The magnitude of measured luminescence 
changes greatly with type of modification. 
 
This result can only be ascribed to unspecific effects of the polymers, constituting a severe 
bias for any measurement of cell proliferation on polymer films. As a consequence, the 
BrdU proliferation assay was no longer applied to cells growing on PCL films. 
3.6.2. Fluorescent cell staining for CLSM 
Because of the possibility that an experimental bias might be introduced through the 
manual transfer of the live/dead-stained cells from the microplate well onto glass slides 
immediately prior to CLSM, another staining method was tested where the adherent cells 
could be fixed on the PCL films. This was achieved with fixative and subsequent staining 
with FITC-conjugated phalloidin (figure 3.27). 
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Figure 3.27. Comparison of live/dead and phalloidin-FITC staining of HUVECs. Per polymer film, 
2×10
4
 cells were seeded and incubated for 96 h. VEGF stimulation was with 25 
ng/ml. Equally treated samples were subjected to either one of the two staining 
protocols and CLSM-imaged with the same fluorescence settings. 
 
3.7. Combined stimulation of endothelial cells with fibronectin and VEGF 
After finding that ECM protein coating could aid endothelial cell adhesion, the question 
arose whether a combined stimulation with VEGF would yield additional benefits for PCL 
endothelialization. For material selection, the previous results were assessed as to the 
most promising types of surface functionalization, and so both plasma chemical 
modifications and silanization with APTES as a representative for wet chemical 
modification were included, along with unactivated PCL. 
When directly compared, precoating with 50 µg/ml fibronectin showed no increased viability 
for HUVECs grown on the four varieties of PCL (figure 3.28), while stimulation with the 
soluble growth factor significantly increased viability on PCL/O2/APTES (p=0.00037; to 
143.0±22.9%) and on PCL/NH3 plasma (p=0.00007; to 129.3±11.7%). The combined 
treatment with fibronectin and VEGF on PCL/O2/APTES led to a lower viability 
(109.4±45.2%) than the pure VEGF stimulus. On the other three varieties of PCL, the 
combination of fibronectin and 25 ng/ml soluble VEGF enhanced HUVEC viability relative to 
VEGF application alone (figure 3.28). The highest viability was seen on PCL/NH3 plasma 
with combinatorial stimulation (147.5±29.3%) which was significantly higher (p=0.014) than 
with VEGF stimulation of HUVECs by itself. 
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Figure 3.28. Separate and combinatorial stimulation of HUVECs growing 
on functionalized PCL varieties with fibronectin and VEGF. 
Shown is the modification-specific effect of stimulation of 
HUVECs for each substrate, i.e. normalized to the viability of 
HUVECs on the uncoated substrate without VEGF 
application (100%). Asterisk denotes statistical significance 
of difference between bracketed groups (* p<0.05). 
 
3.8. Substrate induced changes in endothelial cell mRNA expression 
Adhesion molecule expression on the cell surface is an important indicator for how intact 
the endothelium is. Some of these molecules even serve as biomarkers for the 
inflammatory risk of coronary artery disease [19]. Therefore the comparative analysis of 
gene expression in endothelial cells growing on differently modified substrates should 
provide information on the suitability of those substrates as potential implant material. 
Three such molecules, intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion 
molecule 1 (VCAM-1) and platelet/ endothelial cell adhesion molecule 1 (PECAM-1) were 
selected for qPCR analysis. In addition, eNOS was included as a marker for functional 
endothelia, and IL-8 as a representative for proinflammatory endothelial response to 
different substrates. The necessary standardization of gene expression was achieved 
through normalizing the amounts of individual transcripts to 18S rRNA, representing 
ribosomes which contain approximately 80% of all eukaryotic cellular RNA [77]. For 
normalization in comparative analyses of mRNA levels, 18S rRNA has been found to be 
superior to other housekeeping genes [93]. Taking the results from surface functionalization 
and protein precoating into account, each substrate was presented to the cells in four 
different conditions: 1. without added substances, 2. coated with fibronectin, 3. with soluble 
VEGF and 4. with fibronectin coating and soluble VEGF combined. 
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The amplification plots (figure 2.6) and melting curve analysis (figure 2.5) of the PCR 
products, together with the number of replicates per qPCR sample (table 3.1) demonstrate 
the reproducibility and reliability of the qPCR experiments.  
Cell type Substrate/treatment cDNA 
code 
ICAM-1 VCAM-
1 
PEC-
AM-1 
eNOS 
 
IL-8 
 
HUVEC PCL U1 3 4 4 3 4 
HCAEC PCL C1 2 4 4 0 1 
HUVEC PCL/NH3 plasma U2 3 5 4 4 2 
HCAEC  PCL/NH3 plasma C2 3 4 4 4 4 
HUVEC polystyrene U3 4 4 4 4 3 
HCAEC polystyrene C3 4 3 4 3 4 
HUVEC PCL/O2/APTES U4 4 4 4 4 4 
HCAEC PCL/O2/APTES C4 3 4 4 3 3 
HUVEC PCL/O2 plasma U5 4 3 4 4 4 
HCAEC PCL/O2 plasma C5 4 4 4 4 4 
HUVEC PCL/FN U6 4 4 4 4 4 
HCAEC PCL/FN C6 1 1 4 3 2 
HUVEC PCL/NH3 plasma/FN U7 4 3 4 4 4 
HCAEC PCL/NH3 plasma/FN C7 3 3 3 4 3 
HUVEC polystyrene/FN U8 4 4 4 4 4 
HCAEC polystyrene/FN C8 3 3 4 3 4 
HUVEC PCL/O2/APTES/FN U9 4 2 4 4 3 
HCAEC PCL/O2/APTES/FN C9 4 2 4 4 2 
HUVEC PCL/O2 plasma/FN U10 4 4 4 4 4 
HCAEC PCL/O2 plasma/FN C10 3 3 4 4 3 
HUVEC PCL+VEGF U11 0 0 4 0 2 
HCAEC PCL+VEGF C11 1 2 3 0 0 
HUVEC PCL/NH3 plasma+VEGF U12 4 4 4 4 4 
HCAEC PCL/NH3 plasma+VEGF C12 3 3 3 4 3 
HUVEC polystyrene+VEGF U13 5 4 4 5 5 
HCAEC polystyrene+VEGF C13 4 3 4 4 4 
HUVEC PCL/O2/APTES+VEGF U14 4 4 4 4 4 
HCAEC PCL/O2/APTES+VEGF C14 4 3 4 4 2 
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Cell type Substrate/treatment cDNA 
code 
ICAM-1 VCAM-
1 
PEC-
AM-1 
eNOS 
 
IL-8 
 
HUVEC PCL/O2 plasma+VEGF U15 5 5 5 5 5 
HCAEC PCL/O2 plasma+VEGF C15 2 3 3 1 1 
HUVEC PCL/FN+VEGF U16 4 4 4 4 4 
HCAEC PCL/FN+VEGF C16 1 1 0 0 1 
HUVEC PCL/NH3 plasma/FN+VEGF U17 4 4 4 4 4 
HCAEC PCL/NH3 plasma/FN+VEGF C17 1 2 1 1 1 
HUVEC polystyrene/FN+VEGF U18 4 4 4 4 4 
HCAEC polystyrene/FN+VEGF C18 3 2 2 4 4 
HUVEC PCL/O2/APTES/FN+VEGF U19 0 0 2 0 1 
HCAEC PCL/O2/APTES/FN+VEGF C19 0 0 2 0 1 
HUVEC PCL/O2 plasma/FN+VEGF U20 4 4 4 4 4 
HCAEC PCL/O2 plasma/FN+VEGF C20 2 2 4 1 3 
 
Table 3.1. Overview of qPCR samples and reproducibility of mRNA specific results. 
Shown is the number of successful amplifications per mRNA and sample.  
 
Only samples that gave single-peak melting curves were included in the final analysis. Data 
from unreplicated amplifications have been omitted from the following graphs. All qPCR 
results are presented as fold changes in mRNA abundance relative to cells of the same 
type growing on uncoated polystyrene without VEGF stimulation. The results are presented 
in blocks illustrating the effects of both polymer surface modification and external 
stimulation on mRNA quantity, with each of the examined genes documented separately for 
better comprehension of the multitude of data. 
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Figure 3.29. ICAM-1 expression in (a) HUVECs and (b) HCAECs as a function of PCL 
modification and presence of fibronectin (50 µg/ml) and/or VEGF (25 ng/ml). The 
untreated controls are HUVECs (for a) or HCAECs (for b) grown on polystyrene 
without additives. A fold-change of 0.4 is the same as 2.5-fold downregulation. 
Error bars denote the minimum and maximum of the standard error of the mean. 
 
Because the three adhesion molecules as well as IL-8 are seen as indicators for the initial 
foreign body reaction to freshly implanted stents or grafts [9], the expectation was that their 
expression would be comparatively high in endothelial cells growing on untreated PCL, and 
that surface modification of PCL would alleviate the extent of such an increase. The effects 
of externally added stimuli such as fibronectin and VEGF are harder to predict, but in the 
afore described experiments they had already shown to be beneficial for PCL 
endothelialization, so it might be assumed that mRNA of a functional marker molecule such 
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as eNOS would be more abundant in cells that had received the extra stimulants compared 
to cells that had not. 
 
Figure 3.30. VCAM-1 expression in (a) HUVECs and (b) HCAECs as a function of PCL 
modification and presence of fibronectin (50 µg/ml) and/or VEGF (25 ng/ml). The 
untreated controls are HUVECs (for a) or HCAECs (for b) grown on polystyrene 
without additives. A fold-change of 0.4 is the same as 2.5-fold downregulation. 
Error bars denote the minimum and maximum of the standard error of the mean. 
 
With respect to the three endothelial adhesion molecules, these expectations for 
quantitative changes in mRNA expression were met, particularly for HCAECs: regardless of 
external stimulation, all HCAECs on plain PCL showed a more than 5-fold increase of 
ICAM-1 (figure 3.29b), VCAM-1 (maximum 4211-fold VCAM-1 amount on plain PCL with 
VEGF; figure 3.30b), and PECAM-1 mRNAs (figure 3.31b) compared to the amounts 
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present in control cells growing on uncoated polystyrene. This large increase was 
considerably reduced on PCL surfaces that had been modified, either by APTES or plasma 
activation. It should also be noted here that the threshold cycles for 18S rRNA were 
unusually high for all HCAEC samples from unmodified PCL (22 to 26, compared to 11 to 
17 for the other samples). 
Such a clear trend was not seen in HUVECs. But the prominent decrease in both ICAM-1 
and VCAM-1 mRNA amount exclusively in cells growing on APTES-modified PCL points to 
surface-dependent effects (figures 3.29a and 3.30a). In the case of ICAM-1, the APTES-
specific decrease was seen in both cell types, albeit in HCAECs on a much smaller scale 
than in HUVECs. 
For ICAM-1 and VCAM-1 transcripts, a 5.2-fold and 3.9-fold increase was detected in 
HUVECs growing on fibronectin-coated NH3 plasma activated PCL. Compared with the lack 
of relevant changes in HUVECs growing on PCL/NH3 plasma in the three remaining 
conditions, this result indicates an interplay between this particular surface and fibronectin 
that seems to be abolished in the presence of VEGF. 
The quantitative changes seen in the amounts of PECAM-1 mRNA (figure 3.31) were 
altogether the least pronounced among the adhesion molecules. In HUVECs, PECAM-1 
transcript remained virtually unchanged, with a maximum fold change of only 1.67 after 
stimulation with VEGF alone on PCL/O2/APTES (figure 3.31a). HCAECs growing on PCL 
activated with APTES and NH3 plasma, respectively, showed a pattern that very closely 
resembled the one seen in HUVECs. On O2 plasma activated PCL, the only major change 
in the HCAEC PECAM-1 mRNA amount was with combined fibronectin and VEGF 
stimulation, which led to a 14.7-fold decrease (figure 3.31b). The biological meaning of this 
outlier result cannot be evaluated. Leaving that aside, the mRNA expression of PECAM-1 
in HCAECs falls into the general pattern of overall increase that is much reduced in extent 
when the cells grow on surface activated PCL compared to regular PCL. 
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Figure 3.31. PECAM-1 expression in (a) HUVECs and (b) HCAECs as a function of PCL 
modification and presence of fibronectin (50 µg/ml) and/or VEGF (25 ng/ml). The 
untreated controls are HUVECs (for a) or HCAECs (for b) grown on polystyrene 
without additives. A fold-change of 0.4 is the same as 2.5-fold downregulation. 
Error bars denote the minimum and maximum of the standard error of the mean. 
 
The amount of IL-8 mRNA was expected to increase in general, since IL-8 is a 
proinflammatory cytokine and the endothelial cells were only exposed to their respective 
substrate for 48 h before RNA isolation. Physiologically, this would equate to the initial 
phase of the foreign body reaction, in which IL-8 is involved. In HUVECs, IL-8 transcript 
amounts relative to control cells on tissue culture polystyrene were increased for all four 
substrates and conditions (figure 3.32a), with cells growing on plasma activated PCL 
demonstrating even higher amounts (up to 19.3-fold on fibronectin coated PCL/NH3 plasma 
81 
 
relative to the control) than those growing on regular PCL (maximum 7.3-fold with 
fibronectin and VEGF treatment). Independent of external stimulation, the lowest relative 
amounts of HUVEC IL-8 mRNA were detected when the cells grew on APTES activated 
PCL. 
 
Figure 3.32. IL-8 expression in (a) HUVECs and (b) HCAECs s as a function of PCL modification 
and presence of fibronectin (50 µg/ml) and/or VEGF (25 ng/ml). The untreated 
controls are HUVECs (for a) or HCAECs (for b) grown on polystyrene without 
additives. A fold-change of 0.4 is the same as 2.5-fold downregulation. Error bars 
denote the minimum and maximum of the standard error of the mean. 
 
The quantification of IL-8 transcript in HCAECs (figure 3.32b) yielded results that were not 
as unequivocal as in HUVECs, with relatively increased amounts only in cells grown on 
regular PCL and O2 plasma activated PCL. In contrast, HCAECs on PCL activated with 
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either APTES or NH3 plasma presented with reduced levels of IL-8 mRNA, down to a 10.2-
fold decrease (in HCAECs on PCL/NH3 plasma with VEGF stimulation). Once again, the 
highest increase in mRNA amount was seen on regular PCL (with fibronectin; 24.8-fold), 
compared to which all HCAECs on activated PCL surfaces produced less IL-8 transcript. 
 
Figure 3.33. eNOS expression in (a) HUVECs and (b) HCAECs as a function of PCL modification 
and presence of fibronectin (50 µg/ml) and/or VEGF (25 ng/ml). The untreated 
controls are HUVECs (for a) or HCAECs (for b) grown on polystyrene without 
additives. A fold-change of 0.4 is the same as 2.5-fold downregulation. Error bars 
denote the minimum and maximum of the standard error of the mean. 
 
The trend of marked increase in the amount of transcript in HCAECs grown on regular PCL 
and mitigated increase in HCAECs grown on activated PCL reappeared in the case of 
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eNOS (figure 3.33b). Compared to the control growing on uncoated polystyrene, eNOS 
mRNA remained practically unchanged on plasma activated PCL (maximum 1.3-fold 
increase in HCAECs grown on PCL/O2 plasma/fibronectin), while on PCL/O2/APTES the 
increase was higher (maximum 3.2-fold increase in HCAECs receiving no external 
stimulation). Why the gain was so much more extreme in cells on regular PCL with 
fibronectin coating (234-fold relative to the control) cannot be explained, but there were 
many unreplicated amplifications of eNOS transcript in the HCAEC samples. Overall, 
surface activation of PCL appears to mitigate mRNA abundance of cell adhesion 
molecules, IL-8 and eNOS in HCAECs. 
The picture for HUVEC eNOS mRNA (figure 3.33a) was very different, with relative 
reduction found in every instance. While the observed decrease was only minor on regular 
and APTES activated PCL (minimum of 0.53 on fibronectin coated PCL with VEGF), it 
became more pronounced on the two plasma activated PCL varieties (minimum of 0.33 on 
fibronectin coated PCL/NH3 plasma). That this functional endothelial marker should be 
consistently decreased in terms of mRNA expression was contrary to expectations, but is in 
line with the consistent upregulation of IL-8 expression in HUVECs on PCL.  
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4. Discussion 
 
The scientific aim of this thesis was to examine endothelial cell adhesion to biomaterials 
subjected to different kinds of modification and functionalization, and to characterize cell 
behavior on the various materials differentially by means of biocompatibility testing, 
confocal microscopy and gene expression studies. This shall contribute to the body of 
knowledge on interaction between endothelial cells and implant materials, as 
endothelialization of vascular implant surfaces is one crucial aspect in the aftermath of 
medical intervention in patients with peripheral or coronary artery disease (CAD). The 
problem of endothelial injury during stent or graft implantation cannot be avoided and thus 
represents an inherent risk for later complications. A complex cascade of inflammatory 
processes may culminate in restenosis or thrombosis. Despite significant reductions in 
these complications that have been achieved with the development of DES and DEB, a 
serious risk for the patient remains. A truly safe and efficacious stent would have to 
minimize vessel trauma and inflammation, be mechanically sound yet biocompatible, 
facilitate endothelialization and positive remodeling of the vessel, be anti-restenotic and 
void the need for anti-platelet therapy [94].  
Since the scope was limited to in vitro experiments, two different types of primary 
endothelial cells were examined and compared, for a better understanding of what range of 
response might occur when cells differing in their phenotypes are interacting with 
differentially modified biomaterials.  
4.1. Optimization of in vitro stimulation parameters 
The first series of experiments established an incubation and stimulation regime for primary 
endothelial cells. Firstly, PCL as the polymer of choice was tested for possible cytotoxic 
effects. These could be ruled out for untreated and activated forms of PCL (see figure 3.2.) 
While in undiluted form they performed significantly poorer than polystyrene, the relative 
viability and proliferation of human umbilical vein endothelial cells (HUVECs) incubated in 
the PCL eluates was still higher than of those exposed to thermanox, the other polymer 
tested. Besides, biocompatibility values of the diluted PCL eluates tended to excel those of 
polystyrene, and in vivo any substances detrimental to ECs would be strongly and rapidly 
diluted through the constant flow of blood. It was found that depletion of the endothelial cell 
culture medium of growth factors was essential, to exclude masking effects in the 
subsequent VEGF stimulation experiments (see figure 3.2). There a cumulative effect of the 
growth factor on both viability and proliferation of HUVECs was confirmed. As issues with 
dedifferentiation of primary cells that are experimented on for more than 4 days in a row are 
well documented [10], the general duration of the experiments was limited to 96 hours. This 
85 
 
assured avoidance of said problems, and at the same time it proved to be long enough for 
substantial effects on cell behavior to materialize. Similarly, same-batch cells were only 
employed in experiments between passages three to six, as their responsiveness to VEGF 
stimulation decreased significantly at passage 7 (see figure 3.5). 
The seeding density was another factor that needed consideration. It was found that the 
extent of VEGF responsiveness was dependent on it, with greater increases in cell viability 
and proliferation at lower seeding densities. This is in good agreement with the published 
finding that cell seeding density and growth factor sensitivity are inversely correlated [67], 
as well as with previous studies on endothelial cell – biomaterial interaction, where high 
seeding densities correlated with extensive intercellular interaction that masked substrate 
dependent differences in cell adhesion [88]. Because endothelial cell density after 
implantation of blood contacting devices will initially always be low on the newly introduced 
surface, low seeding densities are recommended for in vitro studies of biomaterial 
applications, such as PCL in this case. Confluence should be avoided because contact 
inhibition will render the cells unresponsive to growth stimuli. For these reasons, HUVECs 
and human coronary artery endothelial cells (HCAECs) were generally seeded at 11,000 
cells/cm2 for biocompatibility testing of the various PCL substrates. In the context of 
endothelial cell culture with polymer, such a density has been successfully tried before [15]. 
Arresting the cell cycle prior to VEGF stimulation proved to greatly enhance the stimulatory 
effect of VEGF, especially on the proliferation rate of HUVECs (see figure 3.10). This result 
is in line with previous studies on growth factor effects on arrested cells [89], and therefore 
temporary cell cycle arrest was introduced as standard treatment of all endothelial cells 
tested on polymer substrates.  
As primary cells can only be cultured for a limited time, the variability of cell responses 
across different cell sources also was an important issue to solve. Individual testing of each 
new batch of cells revealed that in terms of stimulation of proliferation and viability of 
endothelial cells, there is a considerable range. In some cases, a linear dose response to 
VEGF was seen, whereas in others the maximum stimulation was already reached at a 
medium VEGF concentration and above that dropped off (see figure 3.12). As a 
consequence, cells had to pass a quality control step where the stimulation by VEGF had to 
exceed 130% of the unstimulated state in order to be employed in subsequent growth 
experiments on the functionalized polymer. This was done to achieve better reproducibility 
of results. 
In addition, confounding methodological factors were identified and subsequently controlled 
for, excluding a source of bias. 
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4.2. Polymer surface modification 
One important step towards the development of an implant allowing rapid endothelialization 
is optimizing the polymer surface for adhesion of endothelial cells, which the present thesis 
has endeavored to do. While polymers are favored as stent coatings thanks to their 
degradation behavior [95], they are very hydrophobic as unmodified material and therefore 
difficult to colonize with the desired cells. Surface functionalization can reduce that 
hydrophobicity and will exert maximum effect in vitro, because cells are directly seeded 
onto functional groups [96]. This research demonstrates that changes in PCL morphology 
do not significantly increase the attraction of this material for HUVECs and HCAECs (see 
figure 3.13), and that there is a limited influence of chemical surface modification on the 
adhesion of the two types of endothelial cells in vitro (see figure 3.14). The number of 
accessible amino groups on the PCL surface plays a role, for example, since it is the 
highest with APTES modification and the lowest with plasma activation, and HUVECs as 
well as HCAECs seem to prefer the latter (see figure 3.14). Wulf and colleagues have 
shown that ammonia plasma activation of PCL generates up to 12% primary amines of the 
total nitrogen content, while PCL activation with APTES results in 26% primary amines [95]. 
It is possible that the intermediate silane layer (situated between the PCL and the amino 
group on the surface) generated by APTES modification contributes to the observed lower 
viability of the endothelial cells there. 
Wet chemical modification can alter the surface topography, creating a surface that is rough 
and hydrophilic [95] and therefore easier to colonize. The modification solution is assumed 
to penetrate the polymer bulk, but associated changes in bulk properties can be minimized 
in optimal modification conditions. With plasma activation there is no such change in bulk 
properties of the material [97][Junkar et al. 2011]. Also in contrast to wet chemical 
treatments, plasma modification does not necessitate the use of solvents, hence there is no 
risk of the material roughening or degrading [98]. An early study reported enhanced growth 
of bovine aortic endothelial cells over 3 days as a result of the generation of oxygen-
containing surface chemistries by plasma activation [99]. More recently, plasma-activated 
coating has been found to possess very low thrombogenicity in vitro and to be a feasible 
modification of stents with favourable endothelialization rate and neointimal response in 
vivo [26]. The results here point in the same direction, as amongst all modified forms of 
PCL, for HUVECs as well as for HCAECs, both types of plasma activated PCL were found 
to convey the highest relative viability. So despite the lack of significant differences, the 
observed trend is in accordance with previous research demonstrating that adhesion and 
growth of human endothelial cells can be enhanced by changing surface properties of 
polymer substrates [15]. Moreover, the remarkable similarity of the results for HUVECs and 
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HCAECs (see figures 3.13 and 3.14) is an indication for the applicability of these findings to 
endothelial cells in general. 
4.3. Growth factor stimulation 
In animal models, VEGF has been reported to reduce both neointimal growth [75] and 
neovascularisation. Among the effects of VEGF are the upregulation of endothelial NO 
synthase (eNOS) [100] as well as inhibition of platelet and leukocyte activation and of 
smooth muscle cell proliferation [28]. All of these are desirable outcomes in the context of 
vascular stent implantation, which motivated this research in terms of testing the effects of 
VEGF stimulation on endothelial cells growing on a functionalized biopolymer. It is 
demonstrated here that HUVEC and HCAEC proliferation and viability can be profoundly 
and reliably stimulated by VEGF in vitro (figures 3.6 and 3.7) and that the extent of that 
stimulation varies with the adhesion substrate (figures 3.15 to 3.20). 
Previous studies [71, 101, 102] have highlighted the potential for VEGF to optimize the 
outcome of stent angioplasty, which is supported by the findings here because after 
stimulating the viability of HUVECs or HCAECs through plasma chemical activation of the 
substrate they adhere to (figure 3.14), the application of VEGF further increases their 
viability (figures 3.16 and 3.19). The observed magnitude of stimulation through VEGF is in 
good accordance with other studies. A 15% increase in human saphenous vein endothelial 
cell number after 2 days of 1 ng/ml VEGF stimulation has been reported with recombinant 
VEGF [70], while HUVECs exposed to VEGF-eluting stents showed an 11% increase in cell 
growth [71]. Walter et al. reported a 25% increase in re-endothelialization of rabbit external 
iliac artery 10 days after implantation of a VEGF gene-eluting stent compared to a control 
stent [103]. In rats, a single 30-minute application of 100 µg VEGF to the freshly denuded 
intima of the carotid artery resulted in nearly double re-endothelialization compared to 
controls, along with only one third of neointimal thickening 2 weeks after surgery [102]. In 
rabbits, delivery of 100 µg VEGF through a deployed stent to the underlying arterial wall 
accelerated re-endothelialization from 4 weeks post implantation in controls to 1 week, 
along with markedly reduced stent thrombosis [101]. In contrast, VEGF has also been 
found to induce intimal hyperplasia when released from ePTFE grafts [76]. 
Overall, in the present study treatment with VEGF achieved good stimulation of human 
endothelial cells on all substrates tested. It is evident that the type of PCL activation has an 
effect on the extent of VEGF-induced stimulation of HUVEC viability on PCL. A specific 
growth stimulus through VEGF may accelerate the colonization of the luminal stent surface 
with endothelial cells, and a confluent endothelium constitutes an antithrombogenic surface 
[104]. In this regard, there was again great congruence in the results obtained with 
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HUVECs and HCAECs, and this was true for cell viability testing as well as confocal laser 
scanning microscopy (see figures 3.13 to 3.19). 
Recent and current strategies using DES to reduce restenosis focus primarily on 
antiproliferative approaches. Sirolimus and paclitaxel control restenosis through a cytostatic 
mode of action and are therefore the two most commonly used antiproliferative substances 
in DES coatings. Through intracellular signaling cascades, sirolimus and paclitaxel arrest 
the smooth muscle cells (SMCs) in G1 and G2 phase of the cell cycle, respectively. A major 
disadvantage of these antiproliferative drugs is that they are not cell type specific and arrest 
endothelial cell proliferation as well. Sirolimus is known to strongly inhibit VEGF expression 
and secretion, which then results in delayed re-endothelialization and can promote acute 
stent thrombosis [105]. Both sirolimus and paclitaxel, when incorporated into DES, 
produced significant reductions in re-endothelialization compared to bare metal stents, and 
the inhibitory effect of sirolimus was greater than that of paclitaxel [106]. Experimental and 
clinical studies have demonstrated that antiproliferative drugs released from DES delay 
stent re-endothelialization and favor a prothrombogenic environment that can cause late 
thrombosis [107, 108].  
Generally, the initial absence of a functional endothelium is associated with neointimal 
hyperplasia and thrombosis alike [109]. A direct correlation between endothelial defects 
and neointimal thickening in terms of severity and extent was found early on in several rat 
models as well as in human coronary arteries explanted from transplant recipients [[100, 
103]. Subsequent studies have suggested that accelerating re-endothelialization can 
attenuate restenosis and inhibit stent thrombosis. Jeremy and colleagues found that the 
presence of an intact endothelium can suffice to effectively inhibit the proliferation of the 
underlying medial SMCs [110]. This inhibition is mediated via release of vasodilators, i.e. 
NO and heparin sulphate, that keep SMCs in a quiescent state [111, 112]. A prerequisite for 
this is not only complete re-endothelialization but regained functional capacity of the 
endothelium, such that it can regulate vasodilators and thereby halt SMC hyperplasia. An in 
silico model of stent deployment and subsequent shear stress distribution on ECs and NO 
production by ECs revealed that if the endothelium can become functional very quickly 
(within two weeks post implantation), then in-stent restenosis can be avoided altogether 
[113].  
Hence there is a need to use alternative drugs in vascular implant coatings which will 
facilitate the growth of endothelial cells and simultaneously inhibit the growth of SMCs. 
VEGF appears to be a good candidate, especially for combinatorial implant coatings (for 
example, with an antiproliferation drug), as it is specific for endothelial cells and also 
indirectly inhibits SMC proliferation by inducing endothelial NO synthase. Stent-based 
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delivery of naked plasmid DNA encoding human VEGF in rabbits resulted in expression of 
VEGF mRNA and protein for up to 10 days [103]. Interestingly, throughout this period the 
VEGF transcript was localized primarily to the outer media and adventitia of the vessel wall. 
Concurrently the endothelium recovered in terms of anatomy (confluent monolayer) as well 
as function (NO production), and it did so much more rapidly than in animals which had 
been implanted a control stent. This shows that VEGF may also modulate aspects of 
endothelial homeostasis that are more qualitative, apart from facilitating endothelial repair 
at the stent site [102]. At 3 months post procedure, neointimal proliferation in the VEGF-
stented rabbits was also significantly reduced [103]. These findings indicate that VEGF 
incorporated into vascular implants may indirectly reduce the extent of neointimal 
hyperplasia while promoting endothelial recovery.  
Suitability of VEGF is also demonstrated by the data obtained here when the growth factor 
was bound to the polymer surface. Whether it was through adsorption onto sPCL-A or by 
covalent coupling through crosslinkers, VEGF was able to significantly increase the viability 
of HUVECs adhering to sPCL-A. This result corresponds nicely with an animal study where 
PCL scaffolds were implanted in mice and after 7 and 14 days a significant pro-angiogenic 
effect was manifest when VEGF was bound to PCL through heparin [114]. In the sPCL-A 
experiments here, there was no significant difference in the bioactivity of immobilized and 
soluble VEGF. A new study has also found bioactivity of VEGF not to be impaired when it is 
dissolved in chloroform, as is necessary prior to its covalent coupling to polymers [115]. 
This is an important result, as such coupling is essential for long term release of VEGF from 
implants. 
4.4. PCL coating with ECM proteins  
All polymers discovered and used in the vascular implant setting so far have proven to be 
inferior to the native endothelium. Yet certain modifications can be very helpful in 
overcoming this general drawback. Polymer coating with proteins from the ECM provides 
cells with molecular cues for adhesion and so generally facilitates endothelial cell growth 
[76], which is one critical aspect of an implant’s biocompatibility. Besides, it is known that 
the effectiveness of VEGF in inducing blood vessel formation is enhanced when it is bound 
to the ECM [114].  
Here, the endothelialization facilitating effect of matrix proteins was dose-dependent for 
laminin, fibronectin, gelatin and collagen type I, with fibronectin stimulating the growth of 
HUVECs in the most consistent manner (figures 3.22 and 3.23). Because of this and the 
fact that fibronectin is the most adhesive of the ECM glycoproteins [62], the focus of the 
subsequent experiments was put on fibronectin coatings of PCL.  
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While protein coatings are common practice for biomaterials in a cell culture context [85], 
the fast degradation rate of ECM proteins is problematic [35], and it should be kept in mind 
that the ECM also promotes primary lesions and restenosis in humans [102]. This is hardly 
surprising, as the process of blood coagulation starts out with surface adhesion of serum 
protein [98], and the ECM meshwork constitutes a large protein-rich surface. While 
fibronectin possesses good affinity for binding endothelial cells, it also induces platelet 
activation [76]. Moreover, fibronectin not only promotes endothelial cell growth but also 
vascular SMC migration and proliferation as shown in vitro [85]. In that study, only a mixture 
of the ECM components fibronectin, fibrinogen and tropoelastin was able to minimize SMC 
migration whilst still promoting endothelial cell outgrowth. Increased ECM synthesis occurs, 
for example, in response to vascular intimal injury [18]. Arterial neointimal hyperplasia is a 
wound healing response to the significant mechanical trauma at the implant site. This 
process is associated with proliferation and migration of vascular SMCs and ECM 
deposition, which leads to restenosis. Furthermore, in vitro testing of enriched 
hematopoietic progenitor cell cultures revealed a mostly negative impact of collagen type I 
on cell growth [78]. This may be attributed to the fact that collagen I activates platelets, 
which also readily bind to it, resulting in thrombus formation [116]. Also, degraded collagen 
type I has been shown to induce an activated, proliferating SMC phenotype, whereas 
without degradation collagen promotes a quiescent and contractile vascular SMC 
phenotype [117]. Here, the general increase in endothelial colonization of ECM protein-
coated PCL observed in the PCL coating experiments (figure 3.22) indicates that these cell-
adhesive glycoproteins can adsorb onto the polymer without denaturing. This finding is in 
agreement with the literature [118]. 
In spite of the occasional reports on complications related to the use of ECM protein on 
biomaterials [85, 117], several approaches in tissue engineering make use of ECM proteins 
as carriers for bioactive compounds such as growth factors [35]. Furthermore, scaffolds 
designed to guide bone regeneration include collagen for its beneficial properties in wound 
repair, for example [35]. 
While it is known that protein adsorption (especially of cell adhesive glycoproteins present 
in serum) can mask the surface chemistry of implants [118], it appears to be advantageous 
when the desired protein (e.g. fibronectin) is intentionally adsorbed onto the surface. The 
results obtained in this thesis demonstrate that ECM protein precoating is clearly beneficial 
for subsequent adhesion of endothelial cells (figure 3.22). In patients, the increased 
endothelialization should then prevent the migration and proliferation of SMCs. 
Certain combinations of alpha and beta integrin subunits are specific to matrix proteins 
such as fibronectin, laminin and collagen [78]. Through its integrin-binding amino acid 
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sequence arginine-glycine-asparagine (RGD), fibronectin can promote cell attachment, 
spreading and differentiation [119]. A pronounced stimulatory effect of fibronectin on cell 
adhesion and growth has been demonstrated for HUVECs [120] as well as for human aortic 
endothelial cells [121]. On hydrophobic surfaces, fibronectin is likely oriented in such a way 
that its integrin-binding sequences are most accessible [62]; this might account for 
enhanced endothelialization on fibronectin coated PCL (see figures 3.23 and 3.24), as PCL 
in itself is a hydrophobic material. 
In line with previous studies [118], there is an increase in endothelial colonization of PCL 
when the polymer is precoated with ECM protein. When the polymer is coated with proteins 
by adsorption only, as was the case here, the strength of the polymer-protein bond can be 
assumed to be comparatively low. The lower the anchorage strength of fibronectin on the 
modified material, the more cell-matrix focal adhesions can be formed on that material 
[122]. 
Furthermore, proteins of the extracellular matrix are known to suppress HUVEC apoptosis 
[123]. Apoptotic HUVECs are procoagulant and bind platelets [123]. Apoptosis rates 
revealed through TUNEL staining of HUVECs could be reduced as much as 40% in vivo by 
coating collagen modules with fibronectin [123]. This is another beneficial impact of 
fibronectin coatings on endothelialization and might be the cause of the additional gain in 
HUVEC viability upon combined VEGF application and protein coating of plain PCL and 
NH3 plasma activated PCL (see figure 3.28). 
As plasma chemical activation of PCL and silanization with APTES consistently yielded the 
best results in terms of improved viability, proliferation and adhesion of endothelial cells, 
these modifications were selected for subsequent investigations into the effects of cell 
exposure to additional treatments found to be promoting the endothelialization of PCL. 
When ECM protein coating of PCL was combined with VEGF stimulation, the effects seen 
before with fibronectin alone were not reproduced (see figure 3.26). This was most likely 
due to the difference in cell origin, as throughout this study cell source proved to be the 
main cause of variability of cell responsiveness to adhesion promoting external stimuli. 
Another possible explanation is fast degradation of fibronectin. Nonetheless, the 
combination of surface activation, fibronectin coating of the polymer and VEGF produced 
an increase in cell viability that was greater than with VEGF alone. In the case of HUVECs 
growing on PCL/NH3 plasma, this increase was significant, suggesting that the combined 
treatment may aid uniform and fast endothelialization of plasma activated PCL. 
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4.5. Substrate induced changes in endothelial cell mRNA expression 
The pattern of adhesion molecule gene expression seen here has its value most likely with 
regard to the foreign body reaction the examined PCL surfaces might elicit in vivo. The 
results speak in favor of PCL/O2/APTES, where upregulation of the proinflammatory genes 
was least pronounced. APTES modified PCL was included in the qPCR study because it 
emerged from the previous experiments as the most promising type of wet chemical 
activation for endothelialization. Across the four PCL surfaces and two cell types 
investigated, APTES modified PCL caused the least proinflammatory mRNA profile in the 
cells growing on it, with a pronounced relative decrease in HUVEC ICAM-1 and VCAM-1 
mRNAs, and the smallest relative increase in HUVEC IL-8 mRNA. In HCAECs on 
PCL/O2/APTES, ICAM-1 mRNA hardly changed relative to the control (see figure 3.29b), 
and the increase in VCAM-1 mRNA was smaller than on the other substrates (see figure 
3.29b). However, as the experiments were performed with monocultures of endothelial 
cells, the molecular response of the cells to the different surfaces and stimulants at the 
mRNA level cannot be regarded as representative for physiological conditions, where gene 
regulation is substantially influenced by the interplay between different cell types. The 
adhesion molecules in particular are subject to feedback loops of regulation between 
endothelial cells, monocytes, platelets, neutrophils and other leukocytes. Therefore the 
degree and/or the direction of change in the amount of transcripts of the five genes 
investigated could well be different in experimental settings involving coculture with white 
blood cells, and different again in animal models.  
A large proportion of the changes in the transcript amount of the five genes examined here 
was less than two-fold compared to the control and therefore in all likelihood not biologically 
relevant. In their thorough analysis of HUVEC and HCAEC adhesion molecule gene 
expression, Suna and colleagues considered only changes that were more than 2.6-fold as 
significant [17]. The finding here that the highest relative increase in a particular gene 
transcript was always seen in HCAECs corresponds well with their data, where the mRNA 
response to an inflammatory stimulus was generally significantly higher in HCAECs than in 
HUVECs [17]. 
ICAM-1 was the only gene for which the quantitative mRNA response to the different 
substrates and stimuli (see figure 3.29) was broadly similar in both HUVECs and HCAECs 
(e.g 0.62-fold for HUVECs and 0.44-fold for HCAECs on PCL/O2/APTES without additives, 
0.84-fold for HUVECs and 0.69-fold for HCAECs on PCL/NH3 plasma without additives, 
1.43-fold for HUVECs and 1.84-fold for HCAECs on PCL/O2 plasma without additives), and 
even in this case the extent of regulation in some instances differed markedly (e.g. 2.95-
fold downregulation for HUVECs compared with only 1.35-fold for HCAECs on 
PCL/O2/APTES with VEGF). So while the results of cell viability for HUVECs and HCAECs 
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alike indicate that plasma activation of PCL is the most advantageous form of PCL 
modification and are in good accordance, the qPCR results show substantial differences in 
the way that surface modification and growth stimulation impact on gene expression in 
different cell types. 
The observation that both ICAM-1 and VCAM-1 mRNA expression show the overall highest 
increase when HUVECs as well as HCAECs are grown on regular PCL is supported by the 
fact that the two molecules are induced at sites of inflammation [9]; PCL without adhesion-
friendly surface activation was expected to yield the highest degree of foreign body 
response in endothelial cells. The extent of upregulation is in accordance with other 
findings: Suna and colleagues found VCAM-1 transcript in HUVECs and HCAECs 
increased 289-fold and 1141-fold, respectively, in response to 2 h stimulation with 
lymphotoxin-alpha (LTA; a member of the tumor necrosis factor family). Van der Zijpp and 
colleagues reported that fibronectin coating masks the influence of the underlying polymer 
surface on ICAM-1 expression in HUVECs [10]. This in contrast to the findings here, where 
the surface-dependent quantitative changes in ICAM-1 mRNA were also seen when the 
PCL surface was precoated with fibronectin. 
In a few instances (HUVEC ICAM-1 and VCAM-1 on NH3 plasma activated PCL, HCAEC 
IL-8 on O2 plasma activated PCL), the general trend for change in transcript quantity on a 
particular PCL surface showed an aberration when fibronectin alone was added to that 
surface. A possible reason for this observation may lie in conformational changes that the 
underlying polymer surface induces in fibronectin, thus influencing its cell binding properties 
[10]. Such an effect seems likely to be overridden by the presence of VEGF, as indicated by 
the respective qPCR data here. 
The qPCR results for PECAM-1 (see figure 3.31) are in line with those reported by Busch 
and colleagues, who also found that the expression of this adhesion molecule varies with 
polymer substrate [4]. Under static conditions, they saw higher upregulation than under 
flow. Here the most apparent outcome was that, taking both endothelial cell types into 
account, PCL activation with APTES or NH3 plasma left the production of PECAM-1 
transcript in the cells growing on those substrates almost unchanged (see figure 3.31). For 
HUVECs, the biggest factor influencing PECAM-1 mRNA seems to be stimulation with 
VEGF alone, which is in accordance with their adhesion on the various PCL surfaces 
observed by means of CLSM (see figure 3.17). Whether the observed changes indicate 
advantageous properties of activated PCL cannot be clearly assessed, because PECAM-1 
expression in endothelial cells has been reported to be reduced or unchanged, 
respectively, at the protein level upon application of LPS and TNF-, both strong 
proinflammatory stimuli [82]. 
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The comparatively strong increase in IL-8 transcript amount in HUVECs on both nitrogen 
and oxygen plasma activated PCL (see figure 3.31) does not preclude these surfaces from 
further consideration. Firstly, they compared favorably in all the experiments on 
biocompatibility, and secondly, it is already known that resting HUVECs express high levels 
of IL-8 [11]. That this represents a cell type specific characteristic is supported by the 
overall reduced IL-8 response in HCAECs, where most of the samples grown on activated 
PCL demonstrated decreased levels of IL-8 mRNA compared to the unstimulated control 
grown on polystyrene (see figure 3.31b). 
The consistent decrease in eNOS mRNA amount in HUVECs was surprising, because as 
an indicator for proper endothelial functional, more differential expression patterns could be 
expected, with surfaces that had proven beneficial for HUVEC adhesion to modified PCL 
allowing for increased eNOS transcription. The apparent downregulation observed in the 
experimental setup here suggests that HUVECs perhaps need more time to fully settle on 
the newly introduced adhesion substrate before qualitative differences between substrates 
will translate into differential eNOS expression. 
The limitations of the qPCR data presented here are manifold: they were obtained 1. in vitro 
with endothelial cells only, 2. in a static setup, 3. with only one concentration of fibronectin 
and VEGF, and 4. at only one time point. While significant changes in mRNA amounts have 
been detected with only 2 hours of EC stimulation [17], it is possible that the expression, 
especially of target genes such as eNOS, might take longer than the 24 h used here to be 
altered significantly. One explanation for the consistent downregulation of eNOS in 
HUVECs might be that during the relatively short exposure of the cells to the polymer 
substrates, they are still preoccupied with the foreign body reaction. Another possibility, as 
has been speculated by van der Zijpp and colleagues [10], is that in the early phase of 
interaction with the biomaterial, the cells are channeling their energy to adhesion and 
growth on the polymer, and as a consequence transcription of eNOS would not increase 
until monolayer formation is completed.  
The impact of blood flow on the cells is also considerable. There are many studies 
demonstrating that shear stress, as it is present in blood vessels in vivo due to constant 
blood flow, is a major factor influencing the behavior of endothelial cells. So it is feasible 
that the presence of shear stress might be a requirement for the characteristic pattern of 
endothelial gene expression. For example, it is known that eNOS is activated by blood 
shear stress [124] and that local changes in shear stress, which occur at arterial branching 
points and elsewhere, alter the mRNA expression of ICAM-1 and VCAM-1 [12]. The 
application of physiological shear stress, however, was not possible within the framework of 
this thesis. Thus it seems possible that the observed consistent downregulation of eNOS 
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mRNA in HUVECs growing on plain and activated PCL is a result of the absence of shear 
stress. In any event, it seems likely that the occasional drastic regulation of important 
endothelial genes seen here is an artefact, especially as there was no instance in which it 
was reproduced over the two cell types examined.  
So while the qPCR experiments over the 16 conditions (four substrates in four different 
states of stimulation) and two cell types investigated yielded results that were much less 
unequivocal than expected, one important trend confirmed the findings from the studies on 
PCL endothelialization: overall expression of genes that are regarded as markers for 
inflammatory risk in atherosclerosis was substantially increased on PCL without surface 
activation, and these increases were much reduced after chemical activation of the PCL 
surface. Hence, such surface modification appears to be a treatment capable of 
counteracting proinflammatory properties of this polymer.  
4.6. Conclusion 
Re-endothelialization of luminal surfaces is the critical factor after implantation of 
cardiovascular prostheses or stents. This thesis has established an experimental model for 
polymer endothelialization in vitro and examined the potential of morphological, chemical 
and biological modifications of PCL in that regard. Of these, plasma chemical activation of 
the polymer surface yielded the largest increase in HUVEC and HCAEC growth, with 
remarkable similarity between the two cell types. In particular, PCL activated with NH3 
plasma was the material with the most pro-endothelialization properties, while APTES 
activated PCL appeared to induce the lowest extent of inflammatory response in terms of 
mRNA expression. 
Endothelialization can be enhanced by VEGF, both in soluble form and after its 
immobilization on the polymer. There was a high degree of congruence between the two 
cell types in terms of VEGF responsiveness. To ensure endothelial cell stimulation, the 
concentration of VEGF at the substrate/endothelial interface should be equal to a range of 5 
to 50 ng/ml in vitro. 
Precoating of PCL with fibronectin can be beneficial, but in combination with VEGF there is 
no significant cumulative gain for HUVECs or HCAECs. Therefore, pending animal and 
preclinicial studies, it is proposed that the results presented in this thesis can contribute to 
alleviate the shortcomings of presently used cardiovascular implants. In particular, chemical 
and biological surface modification of polymers have the potential to reduce post-
procedural restenosis and thrombosis risks that still remain for patients receiving such 
implants. 
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Abstract 
 
Owing to the aging population in the developed world and increasing prevalence of 
atheroscleoris and cardiovascular disease, vascular implants for the treatment of diseased 
blood vessels are in high demand. While the practice of percutaneous transluminal 
coronary angioplasty (PTCA) with and without stenting has reached a high degree of 
clinical routine, a large number of coronary heart disease patients are still affected by post-
operative complications such as restenosis and thrombosis. These often necessitate further 
medical intervention with open surgery, or in severe cases even cause fatal myocardiac 
arrest.  
The crucial player at the interface of implant and patient is the endothelial cell layer, as it is 
situated on the vessel wall, separating the underlying tissue from the bloodstream. During 
the insertion of vascular implants, endothelial injury is inevitable. At the same time, 
functional recovery of the endothelium is imperative to the implant’s success and the 
patient’s wellbeing. The majority of clinically used implants today, however, have 
shortcomings in allowing the endothelium to recover. As a consequence, too many patients 
are still suffering the aforementioned post-implantation complications. This status quo 
creates a need for modern biomaterials that aid endothelial cells in their adhesion and 
functional recovery post-stenting. In this context, the present thesis systematically 
examines the potential of numerous chemical polymer modifications with regard to 
endothelialization. Human umbilical vein endothelial cells (HUVECs) and human coronary 
artery endothelial cells (HCAECs) are used to characterize endothelial cell responses in 
terms of in vitro viability, adhesion, growth and mRNA expression. As cell substrates, the 
biopolymer poly(ε-caprolactone) (PCL), three morphologically modified and five chemically 
activated forms of PCL are investigated in detail, as well as the impact of PCL precoating 
with proteins of the extracellular matrix and the effect of VEGF, an endothelium specific 
growth factor. 
Firstly, a suitable in vitro model was established and optimized. A number of aspects had to 
be considered so as to exlude potential bias and bring the substrate effects to the fore. 
These included cell culture parameters as well as methodology-based factors such as 
unwanted interaction of the examined material with components of routine laboratory 
assays. Cytotoxicity of the modified polymer was excluded, and the standard experimental 
conditions were set to: exclusive use of cell passages 3 to 6, VEGF test stimulation of each 
cell batch, 24 h reversible arrest of the cell cycle before seeding, an initial cell seeding 
density of 11,000 cells/cm2, VEGF stimulation immediately after cell seeding and for a total 
duration of 96 h at 25 ng/ml. 
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With the experimental setup optimized, primary endothelial cells were seeded on the 
various PCL surfaces and their biocompatibility assessed in a comparative approach. Cell 
viability assays demonstrated plasma activation of PCL to yield a substrate that presents 
both HUVECs and HCAECs with the best conditions for adhesion and growth. These 
results were confirmed by confocal laser scanning microscopy. Then the cells were 
subjected to additional stimulation by vascular endothelial growth factor, applied directly to 
the cell culture medium to boost endothelial cell proliferation on the polymer. For HUVECs, 
the maximum growth response, measured as cell viability and by confocal laser scanning 
microscopy, was again seen on the two plasma activated forms of PCL. For HCAECs, the 
highest stimulation of viability was detected on electrospun PCL and O2 plasma activated 
PCL. 
When, through crosslinkers, VEGF was covalently coupled to a PCL derivative, the viability 
of HUVECs adhering to this substrate was still increased, with no significant loss of the 
stimulatory effect compared to VEGF bound to PCL by surface adsorption. 
In the next step, the various polymer surfaces were coated with extracellular matrix 
proteins, a method that is commonly used in vitro to promote cell adhesion. This proved to 
be beneficial for HUVECs, with fibronectin giving the most consistent benefit among four 
proteins tested. As a consequence, fibronectin precoating of PCL was investigated in 
combination with VEGF stimulation of HUVECs. A trend for additional advantageous effects 
on cell viability was seen, but the increase was significant only for NH3 plasma activated 
PCL. Finally, mRNA expression in both cell types after 24 h stimulation with VEGF on four 
different PCL surfaces with and without fibronectin coating was analysed for eNOS, IL-8 
and the endothelial adhesion molecules ICAM-1, PECAM-1 and VCAM-1. PCL activated 
with aminopropyltriethoxysilane (APTES) was the substrate on which HUVECs and 
HCAECs presented with the least proinflammatory mRNA expression pattern. The most 
notable difference between the two cell types here was that HCAECs always showed the 
highest relative increase in a given mRNA. Overall, however, the qPCR results were 
unequivocal, an outcome that is ascribed to experimental limitations such as the static 
setup and the snapshot sampling at only one time point. 
By examining the impact of morphological, chemical and biological modifications of PCL, 
this thesis contributes towards the existing body of work on polymer endothelialization. It is 
concluded that NH3 plasma chemical activation of PCL combined with VEGF stimulation 
best enhances in vitro endothelialization. 
As an outlook for prospective studies, simulation of the blood vessel environment by 
application of shear stress and co-culture with smooth muscle cells or leukocytes are 
desirable, before the most favorably performing material can be transferred into animal 
studies and preclinical studies. 
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Appendix 
 
A.1. Manufacturing of polymer 
Polymer films were prepared using the following procedure: 1 g PCL (Mw = 65,000 g/mol, 
Sigma-Aldrich, Taufkirchen) was dissolved in 25 ml chloroform (CHCl3). This solution was 
transferred to glass Petri dishes (Ø = 9 cm) where the solvent was allowed to evaporate. 
The resulting film (thickness: approximately 150 µm) was cut from the Petri dish, then 
washed for two days in methanol and for two more days in distilled water. Finally it was 
vacuum dried for seven days at 40°C and 40 mbar. These procedures were carried out 
according to [95]. For salt leaching of PCL, 5 g sodium chloride (NaCl) were added after 
dissolving 1.75 g of polymer in 25 ml CHCl3 and the polymer-salt suspension was poured 
into a Petri dish (Ø = 9 cm). After evaporation of CHCl3 and cutting of the film from the Petri 
dish, a 2 day wash in methanol ensued. The washing with distilled water was extended to 
seven days (with daily water changes) until all salt crystals were washed out and the salt 
free film was then vacuum dried for seven days at 40°C and 40 mbar. For surface 
degradation of PCL with sodium hydroxide (NaOH), each PCL film was immersed in 2 M 
NaOH solution at 50°C for 8 h to increase the number of carboxyl (-COOH) and hydroxyl (-
OH) groups (see figure A.1 i).  
For electrospinning, PCL was dissolved in a 3:1 mixture of chloroform and methanol to 
obtain a 9% (w/v) solution. The PCL fiber mat was prepared with an in-house developed 
electrospinning device. The PCL solution was pumped at a flow rate of 0.1 ml/min to a 
capillary (inner diameter = 0.4 mm) connected to a high voltage power supply. At a voltage 
of +12 kV a fluid jet was ejected from the nozzle opening, and the fibers were collected on a 
metallic mesh (mesh size = 0.5 mm, wire thickness = 0.5 mm), resulting in a PCL fiber mat 
that was vacuum dried at 40°C and 40 mbar for 7 days. These procedures were carried out 
according to [59]. 
 
A.2. Surface activation of PCL via 4,4′-methylenebis(phenyl-isocyanate) (MDI) 
Each PCL sample (Ø = 6 mm) was first degraded in 2 ml sodium hydroxide solution (2 M) at 
50°C for 8 h to increase the number of carboxyl (-COOH) and hydroxyl (-OH) groups (figure 
A.1 i). Then all samples were washed with distilled water and vacuum dried for 12 h. The 
resulting –OH groups on the PCL surface were reacted with MDI, solubilized in 2 ml n-
heptane (1.6 mM) for 5 h under stirring at 50°C (figure A.1 ii). After washing with n-heptane 
and vacuum drying for 12 h, the terminal isocyanate (-NCO) groups of PCL underwent 
aminolysis or hydrolysis to amino (-NH2) groups by means of 2 ml ammonia solution (25 %) 
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(figure A.1 iii). Finally the PCL samples were once more washed with distilled water and 
vacuum dried.  
 
 
Figure A.1. Reaction scheme of chemical surface modification of PCL with MDI: (i) after alkaline 
hydrolysis, (ii) coupling of MDI, (iii) formation of terminal amino groups. 
 
A.3. Surface activation of PCL via hexane-1,6-diamine (HMDA) 
For generating amino groups (figure A.2)., non-activated PCL films were immersed in 
hexane-1,6-diamine (HMDA) in isopropanol (78 mg/ml), stirred in HMDA solution for one 
hour at 37°C and finally washed with pure water, as described by Zhang and Hollister [125]. 
 
 
Figure A.2. Reaction scheme for generation of terminal amino groups on PCL 
via aminolysis with HMDA. 
A.4. Surface activation of PCL via aminopropyltriethoxysilane (APTES) 
As described in detail in [51], the PCL samples (Ø = 6 mm) were first modified by means of 
O2 plasma activation (capacity 30 %), then incubated in 2 ml APTES (0.2 M in water) and 
(i)
(ii)
 
(iii)
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stirred for 24 h at room temperature. Through the addition of APTES, which acts as spacer, 
an amino-functionalized silyl ether containing terminal amino groups was generated (figure 
A.3). In the end the samples were rinsed with water and vacuum dried for 12 h.  
O2-plasmaPCL surface
APTES
O
Si OO
NH2
Si O
O
NH2
OH
OH OH OH
 
Figure A.3. Reaction scheme for generation of terminal amino groups on PCL by means of 
O2 plasma activation and reaction with APTES. 
 
A.5. Surface activation of PCL via ammonia plasma  
The NH3 plasma activation process for PCL was performed via plasma etching (PE) 
electrode in ammonia (NH3) gas in a radio frequency (RF) plasma generator (frequency 
13.56 MHz, Diener Electronic GmbH & Co. KG, Ebhausen) at 30 W and a low pressure of 
0.3 mbar (figure A.4). Plasma chemical activation parameters were optimized to yield 
maximum wettability of the activated material. 
 
Figure A.4. Reaction scheme for generation of terminal amino groups on PCL with NH3 
plasma. 
 
A.6. Surface activation of PCL via oxygen plasma  
The O2 plasma activation process for PCL was also performed via plasma etching (PE) 
electrode in an oxygen plasma generator (frequency 13.56 MHz, Diener Electronic, 
 X = NH2, and other nitrogenous groups
X
NH3-plasmaPCL surface
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Ebhausen) at 100 W and 0.3 mbar (figure A.5). For cell culture experiments, all activated 
polymer films were washed three times in water for an hour at room temperature with gentle 
shaking. The procedure was repeated with 0.05% Tween 20 in water and finally with pure 
water again. 
 
Figure A.5. Reaction scheme for generation of terminal oxygenous groups on PCL with O2 
plasma. 
 
A.7. Covalent coupling of VEGF to sPCL-A 
Immobilization of vascular endothelial growth factor (VEGF) to 4-star-shaped poly(ε-
caprolactone) with terminal acrylate groups (sPCL-A) was performed either by adsorption 
or by employing the crosslinkers N,N-disuccinimidyl carbonate (DSC) or 1-ethyl-3-[3-
dimethyl-aminopropyl]carbodiimide (EDC) and N-hydroxysuccinimide (NHS) in 
combination. Crosslinking with DSC results in the formation of ester bonds which can be 
cleaved by hydrolysis. In contrast, crosslinking with EDC/NHS leads to stable amid bonds, 
such that VEGF is coupled to sPCL-A in a way that is physiologically more stable.  
 
A.8. Characterization of functionalized polymer 
For confirmation of surface modification, the polymer films were examined by means of 
contact angle measurement (with water to determine hydrophilicity), 4-chloro-7-nitrobenzo-
2-oxa-1,3-diazole (NBD-Cl) labeling (where fluorescence intensity correlates with the 
number of amino groups present) and environmental scanning electron microscopy (ESEM) 
as previously described [95]. These measurements are shown in figure A.6. 
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Figure A.6. Contact angle Θ of water as per sessile drop static measurement 
(n≥10) as a function of PCL modification. 
 
A.9. Problem of teflon rings 
In order to standardize the growth conditions for cells inside the microtiter wells, teflon rings 
were used to fix the circular substrate discs at the bottom of the wells.  
 
Figure A.7. The presence of teflon rings during measurement of cell proliferation 
and viability greatly influences biocompatibility test results. The 
outer diameter of the rings was always 6.1 mm, while their 
thickness varied from 0.8 to 1.9 mm. Shown is the relative intensity 
compared to cells incubated and measured without rings (100%) 
after 96 h of growth. Asterisks denote statistical significance of 
difference to that 100% control. 
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Figure A.8. ECM protein precoating of PCL positively 
impacts on HUVEC adhesion to the polymer. 
CLSM micrographs of HUVECs grown for 72 h 
on PCL coated with fibronectin, laminin or 
collagen type I (50 μg/ml each). After formalin 
fixation on the PCL films, cells were stained 
with phalloidin-FITC (green) and ethidium 
dimer (red). (a) uncoated PCL, (b) 
PCL+laminin, (c) PCL+ collagen type I, (d) 
PCL+ fibronectin. Scale bar: 200 μm 
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f 
qcrit 
α=0.05 
qcrit 
α=0.01 
qcrit 
α=0.001 
  f 
qcrit 
α=0.05 
qcrit 
α=0.01 
qcrit 
α=0.001 
1 1.409 1.414 1.414   19 1.936 2.454 2.975 
2 1.645 1.715 1.730   20 1.937 2.460 2.990 
3 1.757 1.918 1.982   25 1.942 2.483 3.047 
4 1.814 2.051 2.178   30 1.945 2.498 3.085 
5 1.848 2.142 2.329   35 1.948 2.509 3.113 
6 1.870 2.208 2.447   40 1.949 2.518 3.134 
7 1.885 2.256 2.540   45 1.950 2.524 3.152 
8 1.895 2.294 2.616   50 1.951 2.529 3.166 
9 1.903 2.324 2.678   100 1.956 2.553 3.227 
10 1.910 2.348 2.730   200 1.958 2.564 3.265 
11 1.916 2.368 2.774   300 1.958 2.566 3.271 
12 1.920 2.385 2.812   400 1.959 2.568 3.275 
13 1.923 2.399 2.845   500 1.959 2.570 3.279 
14 1.926 2.412 2.874   600 1.959 2.571 3.281 
15 1.928 2.423 2.899   700 1.959 2.572 3.283 
16 1.931 2.432 2.921   800 1.959 2.573 3.285 
17 1.933 2.440 2.941   1000 1.960 2.576 3.291 
18 1.935 2.447 2.959 
     
 
Table A.1. Threshold values for the outlier test after Nalimov. f= degrees of freedom  
(= n-2), qcrit= critical threshold, = level of significance. The table values 
used here were for =0.05. 
 
 
 
 
